Obesity inhibitor, anti-dementia agent, deodorant, anti-aging agent, anti-saccharification agent, anti-type I allergy agent, anti-hypertensive agent, flavor-improving agent, muscle-enhancing agent, and bone metabolism-improving agent

Abstract

The present invention relates to an obesity inhibitor, an anti-dementia agent, a deodorant agent, an anti-aging agent, an anti-saccharification agent, an anti-type I allergy agent, an anti-hypertensive agent, a flavor-improving agent, a muscle-enhancing agent, and a bone metabolism-improving agent. One aspect of the present invention provides an obesity inhibitor, an anti-dementia agent, a deodorant agent, an anti-aging agent, an anti-saccharification agent, an anti-type I allergy agent, an anti-hypertension agent, a flavor-improving agent, a muscle-enhancing agent, and a bone metabolism-improving agent containing a decomposed extract of bagasse as an active ingredient.

Description

[0001] This application is a divisional application of the invention patent application with the application date of May 30, 2019, the application number of 201980035152.6, and the invention name of "obesity inhibitor, anti-dementia agent, deodorant, anti-aging agent, anti-glycation agent, anti-type I allergy agent, anti-hypertensive agent, flavor improver, muscle enhancer, and bone metabolism improver". TECHNICAL FIELD

[0002] The present application relates to an obesity inhibitor, an anti-dementia agent, a deodorant, an anti-aging agent, an anti-glycation agent, an anti-type I allergy agent, an anti-hypertensive agent, a flavor improver, a muscle enhancer, and a bone metabolism improver. BACKGROUND

[0003] Obesity, particularly obesity caused by accumulation of visceral fat, has become a global health problem as a cause of metabolic syndrome. If the mechanism of obesity is systematically studied, it is a state in which adipocytes accumulate a large amount of fat and hypertrophy, and further, a state in which the number of hypertrophied adipocytes proliferates greatly.

[0004] In order to suppress obesity, moderate exercise and restriction of calorie intake are effective, but in recent years, in order to more effectively suppress obesity, development of an obesity inhibitor is being conducted. Patent Literature 1 discloses that a kiwi fruit extract is effective in suppressing obesity.

[0005] On the other hand, dementia refers to a state in which brain cells die or function deteriorates due to various causes, thereby causing various disorders or troubles in life. With the onset of dementia, the entire brain shrinks, and sometimes body functions are lost.

[0006] Therefore, in recent years, research on components that give an effect of suppressing dementia is actively conducted. For example, Patent Literature 2 discloses that royal jelly shows anti-dementia activity.

[0007] On the other hand, in recent years, deodorants for deodorizing or deodorizing the following malodors have been marketed, the malodors including malodors produced by living organisms such as humans and animals, and malodors produced by indoor, indoor, refrigerator, washroom, livestock shed, fish tank, factory, and malodors produced by household waste, industrial waste. On the other hand, among such deodorants, from the viewpoint of consideration for the environment after disposal, it is even desired to use a deodorant derived from a natural product in environmental use. As a deodorant derived from a natural product, Patent Literature 3 discloses a deodorant using a distillate derived from sugar cane as an effective component.

[0008] On the other hand, the skin is a three-layer structure of the epidermis, the dermis, and the subcutaneous tissue. In the dermis, type I collagen is aggregated to form bundles, thereby playing a role as a support of the dermis, and around the bundles, components such as elastin, hyaluronic acid, and the like are present. When these components are reduced or decomposed due to aging or irradiation of ultraviolet rays, or the like, the skin loses tightness and luster, and wrinkles are easily formed.

[0009] In order to suppress such aging of the skin, various anti-aging agents have been studied. Patent Literature 4 discloses an anti-aging agent characterized by containing an extract from a Rhus chinensis and / or a Camellia oleifera as an effective ingredient. Patent Literature 5 discloses an anti-aging agent containing an extract of one or two or more kinds of plants selected from the genus Podocarpus of the family Podocarpaceae. Patent Literature 6 discloses an anti-aging agent characterized by containing an extract of Zanthoxylum piperitum as an effective ingredient. Patent Literature 7 discloses a collagen production promoter, a collagenase inhibitor, and an elastase inhibitor characterized by containing an extract from a leaf portion of a Averrhoa carambola as an effective ingredient.

[0010] On the other hand, glycation, which is also called the Maillard reaction, is a non-enzymatic chemical reaction of an amino acid or a protein with a reducing sugar discovered in 1912 by a French scientist L.C. Maillard. In the field of food chemistry in which coloring, change in aroma or flavor, or the like occurring in heating of food, glycation is attracting attention.

[0011] Glycation in a living body is a reaction in which a carbonyl group of a reducing sugar such as glucose and a protein undergo a non-enzymatic reaction, form a schiff base, and then through Amadori rearrangement, become a glycation protein as an irreversible substance, generate reaction intermediates centered on carbonyl compounds such as 3-deoxyglucose ketone aldehyde (3DG), glyoxal, methylglyoxal, glyceraldehyde, glutaraldehyde, and the like, and then generate advanced glycation end products (AGEs).

[0012] In recent years, various studies have been made on the relationship of AGEs with aging of human skin, arteriosclerosis, diabetic diseases, three major complications of diabetes (neuropathy, retinopathy, nephropathy), adult disease, and the like, and anti-glycation agents are used in treatment, improvement, and anti-aging, prevention of these diseases. In addition, various anti-glycation agents have been proposed so far. For example, Patent Literature 8 discloses an anti-glycation agent containing a concentrated extract of sake lees as an effective ingredient.

[0013] On the other hand, allergy is defined as "systemic or local damage to an organism caused by an immune response." Allergic reactions can be categorized into types I to IV. Types I, II, and III allergic reactions are humoral immunity involving serum antibodies, while type IV allergic reactions are cellular immunity based on sensitized lymphocytes.

[0014] Type I allergy is also known as immediate allergy or anaphylactic allergy. Symptoms of type I allergy include hay fever and urticaria. These symptoms are common in the population, leading to a demand for effective anti-type I allergy agents. For example, Patent Document 9 discloses a cosmetic or topical skin preparation that exhibits an anti-allergic effect by combining a carnitine derivative and / or a carnitine derivative with an effect enhancer.

[0015] On the other hand, hypertension is a condition where blood pressure remains above the normal range. Hypertension is a lifestyle disease that can cause complications to major organs such as the brain, heart, and kidneys, making it a major problem.

[0016] In recent years, natural substances with antihypertensive effects have been explored. For example, Patent Document 10 discloses an antihypertensive agent containing a mung bean protein hydrolyzate.

[0017] Meanwhile, flavor improvers are currently known that selectively remove or reduce unpleasant tastes in foods and drinks, such as bitterness, astringency, sourness, greenness, egginess, irritation, metallic taste, and cooking odor. For example, Patent Document 11 describes a flavor improver for foods and drinks containing a sugarcane-derived distillate as an active ingredient, the flavor improver being a fraction obtained by passing the distillate obtained by distilling sugarcane juice through a column filled with a synthetic adsorbent as a fixed carrier, and eluting the components adsorbed to the synthetic adsorbent with a solvent selected from water, ethanol, and mixtures thereof. In addition, Patent Document 12 describes a method for improving the flavor of a food or beverage by adding an extract derived from sugarcane as an active ingredient to the food or beverage, wherein the extract derived from sugarcane is a fraction obtained by treating a raw material selected from sugarcane juice, a solvent extract of sugarcane, and molasses derived from sugarcane by column chromatography using a fixed carrier; and the improvement in the flavor of the food or beverage is any one of improving the salt flavor of a food or beverage containing salt, improving the egg flavor of a food or beverage containing eggs, and improving the spice flavor of a food or beverage containing spices.

[0018] On the other hand, muscle is formed by differentiation of muscle cells. In the differentiation of muscle cells, myoblasts as precursor cells proliferate to a certain number of cells, move to a predetermined area of muscle, and fuse with each other to become differentiated polygonal myotube cells. Then, in the myotube cells, genes that exhibit muscle-specific traits such as muscle contraction proteins and specific enzymes are expressed, thereby constructing a muscle contraction apparatus.

[0019] The function of muscle is also closely related to mitochondria in muscle cells. The main function of mitochondria is to produce energy (ATP) in the TCA cycle. In order to improve the metabolic function of muscle, it is important to increase the amount of mitochondria or to improve their activity.

[0020] Since enhancing muscle and improving its function are important in maintaining and improving motor function and maintaining physical health, various means for enhancing muscle have been studied. For example, Patent Literature 13 discloses a muscle differentiation induction promoter that uses a fermented extract of rice bran and / or rice germ as an effective ingredient. In addition, Patent Literature 14 discloses a method of activating mitochondria during exercise using glutathione.

[0021] On the other hand, bone is reconstructed (bone remodeling) by repeating bone metabolism based on "bone formation" by osteoblasts (cells that make bone) and "bone resorption" by osteoclasts (cells that destroy bone), and the bone mass is maintained by the balance of these two types of cells. Osteoblasts, like cells of fat and muscle, are derived from mesenchymal stem cells, but osteoclasts, like red blood cells and white blood cells, are derived from blood cells.

[0022] Bone metabolism is initiated by the appearance of a membrane protein called RANKL on the surface of osteoblasts. When RANKL binds to RANK, a receptor of blood cells, the blood cells differentiate into osteoclasts. The differentiated and matured osteoclasts destroy bone (bone resorption), and then form the same amount of bone as the absorbed osteoblasts. However, due to factors such as aging and decreased ovarian function, the balance of bone metabolism (the balance between bone resorption and bone formation) is lost, and the bone mass (bone density) decreases, which can lead to bone-related diseases such as fractures, osteoporosis, and osteomalacia.

[0023] Therefore, there is a demand for components that help suppress bone-related diseases by improving bone metabolism including bone formation and bone resorption. For example, Patent Literature 15 discloses a bone formation promoter that uses at least either of Acai extract and Actinidia polygama extract as an effective ingredient.

[0024] Prior Art Documents

[0025] Patent Literature

[0026] Patent Literature 1: Japanese Patent Application Laid-Open No. 2010-503609

[0027] Patent Literature 2: International Publication No. 2017 / 078175

[0028] Patent Literature 3: Japanese Patent Application Laid-Open No. 2001-087365

[0029] Patent Literature 4: Japanese Patent Application Laid-Open No. 2010-83786

[0030] Patent Literature 5: Japanese Patent Application Laid-Open No. 2010-70501

[0031] Patent Literature 6: Japanese Patent Application Laid-Open No. Hei 11-79971

[0032] Patent Literature 7: Japanese Patent Application Laid-Open No. 2002-226323

[0033] Patent Literature 8: Japanese Patent Application Laid-Open No. 2013-213021

[0034] Patent Literature 9: Japanese Patent Application Laid-Open No. 2014-114289

[0035] Patent Literature 10: Japanese Patent Application Laid-Open No. 2006-219420

[0036] Patent Literature 11: Japanese Patent Application Laid-Open No. 2001-299264

[0037] Patent Literature 12: Japanese Patent Application Laid-Open No. 2003-265135

[0038] Patent Literature 13: Japanese Patent Application Laid-Open No. 2017-193947

[0039] Patent Literature 14: Japanese Patent Application Laid-Open No. 2018-27983

[0040] Patent Literature 15: Japanese Patent Application Laid-Open No. 2018-150240

[0041] Non-Patent Literature

[0042] Non-Patent Literature 1: Japanese Journal of Pharmacology, 130(2), pp 112-116, 2007 SUMMARY

[0043] Problem to be solved by the invention

[0044] An object of the present application is to provide novel obesity inhibitors, anti-dementia agents, deodorants, anti-aging agents, anti-glycation agents, anti-type I allergy agents, antihypertensive agents, flavor improvers, muscle enhancers, and bone metabolism improvers.

[0045] Solution for solving the problem

[0046] The present inventors have found, through in vitro tests, that a decomposed extract of sugar cane bagasse has an obesity-inhibiting effect, an anti-aging effect, an anti-glycation effect, an anti-type I allergy effect, an anti-hypertensive effect, a muscle-enhancing effect, and a bone metabolism-improving effect.

[0047] The present inventors have also found, through in vivo tests, that a decomposed extract of sugar cane bagasse has an effect of improving short-term memory disorder due to accumulation of β-amyloid.

[0048] The present inventors have also found that a decomposed extract of sugar cane bagasse has an excellent deodorizing effect, particularly on food and drink. Furthermore, the present inventors have also found that a decomposed extract of sugar cane bagasse has a food and drink flavor-improving effect that is different from the component properties described in Patent Documents 11 and 12.

[0049] In a first aspect of the present application, an obesity inhibitor is provided as one mode, which contains a decomposed extract of sugar cane bagasse as an effective component. According to the obesity inhibitor of the present application, obesity can be effectively inhibited.

[0050] The obesity inhibitor of the present application can be based at least on a fat accumulation-inhibiting effect. The obesity inhibitor of the present application has at least an effect of inhibiting accumulation of fat in fat cells. Inhibition of excessive accumulation of fat can be an effective means of preventing obesity, and thus obesity can be inhibited by the obesity inhibitor of the present application.

[0051] The first aspect of the present application can also provide a fat accumulation inhibitor, which contains a decomposed extract of sugar cane bagasse as an effective component.

[0052] A second aspect of the present application provides an anti-dementia agent, which contains a decomposed extract of sugar cane bagasse as an effective component.

[0053] The second aspect of the present application can also provide a short-term memory disorder-improving / inhibiting agent, which contains a decomposed extract of sugar cane bagasse as an effective component.

[0054] A third aspect of the present application provides a deodorant, which contains a decomposed extract of sugar cane bagasse as an effective component.

[0055] A fourth aspect of the present application provides an anti-aging agent, which contains a decomposed extract of sugar cane bagasse as an effective component. The anti-aging agent of the present application has an excellent anti-aging effect by containing a decomposed extract of sugar cane bagasse as an effective component.

[0056] In the fourth aspect of the present application, an extracellular matrix-degrading enzyme inhibitor can also be provided as another mode, which contains a decomposed extract of sugar cane bagasse as an effective component. In the fourth aspect of the present application, a fibroblast-activating agent can also be provided as a further another mode.

[0057] The fifth aspect of the present application relates to an anti-glycation agent containing a decomposed extract of bagasse as an effective ingredient. The anti-glycation agent of the present application is excellent in anti-glycation activity because it contains a decomposed extract of bagasse as an effective ingredient.

[0058] The anti-glycation agent described above is excellent in anti-glycation activity, and thus can be suitably used as an anti-glycation food or drink.

[0059] In the sixth aspect of the present application, as one mode, an anti-type I allergy agent containing a decomposed extract of bagasse as an effective ingredient is provided. The anti-type I allergy agent according to the present application can inhibit (treat, alleviate, or prevent) the symptoms of type I allergy.

[0060] The anti-type I allergy agent of the present application can be based on the inhibition of degranulation of mast cells or basophils.

[0061] The mechanism of type I allergy reaction is described below.

[0062] (1) If an antigen (allergen) such as pollen or mites invades into a living body, helper T cells (Th2 cells) issue an order to differentiate B cells into immunoglobulin E (IgE) antibody-producing cells.

[0063] (2) IgE antibodies specific to the antigen are produced from the IgE antibody-producing cells.

[0064] (3) The IgE antibodies bind to mast cells or basophils, and by binding again to the antigen, chemical mediators such as histamine and leukotrienes are secreted (degranulated), and the symptoms of allergy appear.

[0065] The anti-type I allergy agent of the present application at least has the effect of inhibiting the degranulation of mast cells or basophils. Therefore, the anti-type I allergy agent according to the present application can effectively inhibit the symptoms of type I allergy.

[0066] In the sixth aspect of the present application, as another mode, a degranulation inhibitor of mast cells or basophils containing a decomposed extract of bagasse as an effective ingredient can also be provided.

[0067] In the seventh aspect of the present application, as one mode, an anti-hypertensive agent containing a decomposed extract of bagasse as an effective ingredient is provided. The anti-hypertensive agent of the present application is excellent in anti-hypertensive effect by containing a decomposed extract of bagasse as an effective ingredient.

[0068] In the seventh aspect of the present application, as another mode, an angiotensin converting enzyme inhibitor containing a decomposed extract of bagasse as an effective ingredient can also be provided.

[0069] The 8th aspect of the present application provides a flavor improver containing a decomposed extract of bagasse. The flavor improver can be a flavor improver for enhancing a pleasant flavor of a food or drink. The flavor improver can be a flavor improver for reducing an unpleasant taste of a food or drink.

[0070] The 8th aspect of the present application can also provide a food or drink containing the above-described flavor improver.

[0071] The 8th aspect of the present application can also provide a pleasant flavor enhancer for a food or drink containing a decomposed extract of bagasse. The 8th aspect of the present application can also provide an unpleasant taste reducer for a food or drink containing a decomposed extract of bagasse.

[0072] The 9th aspect of the present application provides a muscle enhancer containing a decomposed extract of bagasse as an effective ingredient.

[0073] The 9th aspect of the present application can also provide a myoblast cell differentiation promoter containing a decomposed extract of bagasse as an effective ingredient. The 9th aspect of the present application can also provide a mitochondrion activator containing a decomposed extract of bagasse as an effective ingredient.

[0074] The 10th aspect of the present application provides a bone metabolism improver containing a decomposed extract of bagasse as an effective ingredient.

[0075] The 10th aspect of the present application can also provide a bone formation promoter containing a decomposed extract of bagasse as an effective ingredient. The 10th aspect of the present application can also provide a bone resorption inhibitor containing a decomposed extract of bagasse as an effective ingredient.

[0076] The decomposed extract of bagasse in the present application can be a decomposed treatment liquid obtained by at least one decomposed treatment selected from the group consisting of alkali treatment, hydrothermal treatment, acid treatment, subcritical water treatment, and explosive treatment.

[0077] The decomposed extract of bagasse can be a fraction obtained by passing the decomposed treatment liquid through a column packed with a stationary carrier. The stationary carrier is preferably a synthetic adsorbent or an ion exchange resin.

[0078] When the stationary carrier is a synthetic adsorbent, the decomposed extract of bagasse can be a fraction obtained by eluting components adsorbed to the synthetic adsorbent with at least one solvent selected from the group consisting of water, methanol, ethanol, and a mixture thereof.

[0079] The synthetic adsorbent is preferably an aromatic resin, an acrylic methacrylic resin, or an acrylonitrile aliphatic resin.

[0080] The decomposed extract of bagasse can be a fraction obtained by passing a decomposed liquid through a column filled with a synthetic adsorbent as a fixed carrier, and eluting the components adsorbed on the synthetic adsorbent with a mixed solvent of ethanol and water. In this case, the synthetic adsorbent is an unsubstituted aromatic resin, the column temperature is 20 to 60° C., and the volume ratio of ethanol to water (ethanol / water) in the mixed solvent can be 50 / 50 to 60 / 40.

[0081] Effects of the invention

[0082] According to the present invention, novel obesity inhibitors, anti-dementia agents, deodorants, anti-aging agents, anti-glycation agents, anti-type I allergy agents, antihypertensive agents, flavor improvers, muscle strengthening agents, and bone metabolism improvers can be provided. BRIEF DESCRIPTION OF THE DRAWINGS

[0083] Figure 1 These are micrographs showing the results of staining of accumulated fat droplets in the precursor cells (undifferentiated a1-1), the positive control a1-1, the comparative example a1-1, and the adipocytes of Example a1.

[0084] Figure 2 It is a graph showing the fat accumulation rates of Comparative Example a1-1, Positive Control a1-1, and Example a1.

[0085] Figure 3 These are micrographs showing the results of staining of fat droplets accumulated in the precursor cells (undifferentiated a1-2), the adipocytes of Comparative Example a1-2, and Example a2.

[0086] Figure 4 It is a graph showing the fat accumulation rates of Comparative Example a1-2 and Example a2.

[0087] Figure 5 It is a graph showing the evaluation results in the Y-shaped maze test.

[0088] Figure 6 It is a graph showing the results in Test Example e1.

[0089] Figure 7 It is a graph showing the results in Test Example e3.

[0090] Figure 8 It is a graph showing the degranulation rates of Examples f1 to f3, Comparative Example f1, and the positive control.

[0091] Figure 9 It is a graph showing the degranulation rates of Examples f4 to f6 and Comparative Example f1.

[0092] Figure 10is a graph showing the elution pattern in the extract derived from sugar cane in test h.

[0093] Figure 11 is a microscope observation result of osteoclasts for test example j2. DETAILED DESCRIPTION

[0094] Embodiments of the present application are described below. However, the present application is not limited to the following embodiments.

[0095] <Decomposed extract of sugar cane residue>

[0096] "Sugar cane residue" typically refers to sugar cane residue discharged in a sugar manufacturing process in a raw sugar factory. The sugar cane residue discharged in the sugar manufacturing process in the raw sugar factory includes not only final sugar cane residue coming out of a final press, but also broken pieces of sugar cane engaged in a presser including a first press and a presser thereafter. Suitable sugar cane residue is sugar cane residue discharged after sugar juice is pressed by a press process in a raw sugar factory. Depending on the type of sugar cane, the time of harvest, and the like, the moisture content, sugar content, and their composition ratio in the sugar cane residue differ, but any of these sugar cane residues can be used in the present application. Furthermore, in one embodiment, as the raw material, the sugar cane residue can also be used, as in a raw sugar factory, for example, sugar cane residue remaining after sugar cane is pressed in a brown sugar factory, or sugar cane residue after sugar cane is pressed in a sugar juice by a small-scale implementation at a laboratory level.

[0097] The decomposed extract of sugar cane residue can be a decomposition treatment liquid of sugar cane residue (and / or a processed product thereof) in one embodiment. The decomposition treatment liquid can be obtained by at least one or more decomposition treatments selected from the group consisting of alkali treatment, hydrothermal treatment, acid treatment, subcritical water treatment, and explosive treatment. The decomposition treatment of sugar cane residue in the present specification requires destruction of part or all of the chemical structure of lignin, cellulose, and / or hemicellulose. From the viewpoint of easy availability of the decomposed extract of sugar cane residue, the decomposition treatment is preferably alkali treatment or hydrothermal treatment.

[0098] The alkali treatment can be a treatment in which sugar cane residue is brought into contact with an alkaline solution. As a method of bringing sugar cane residue into contact with an alkaline solution, for example, a method in which an alkaline solution is sprayed on sugar cane residue, a method in which sugar cane residue is immersed in an alkaline solution, and the like can be listed. In the method in which sugar cane residue is immersed in an alkaline solution, the immersion can also be performed while stirring the mixture of sugar cane residue and the alkaline solution.

[0099] As the alkaline solution, an aqueous sodium hydroxide solution, an aqueous potassium hydroxide solution, an aqueous ammonia solution, and the like can be listed. The alkaline solution can use one of these solutions alone or two or more of these solutions in combination. From the viewpoint of being inexpensive and easy to use in a food manufacturing process, the alkaline solution is preferably an aqueous sodium hydroxide solution.

[0100] From the viewpoint of shortening the processing time of the decomposition treatment, the temperature (liquid temperature) of the alkaline solution is preferably 40°C or higher, more preferably 100°C or higher, and further preferably 130°C or higher. From the viewpoint of preventing the residual polysaccharides in the decomposition treatment liquid, the temperature of the alkaline solution is preferably 250°C or lower, more preferably 200°C or lower, and further preferably 150°C or lower. The temperature of the alkaline solution can be 40 to 250°C, 40 to 200°C, 40 to 150°C, 100 to 250°C, 100 to 200°C, 100 to 150°C, 130 to 250°C, or 130 to 200°C, 130 to 150°C.

[0101] The alkali treatment can be performed under normal pressure, or can be performed under pressure. When performed under pressure, the pressure can be 0.1 MPa or higher, or 0.2 MPa or higher, and can be 4.0 MPa or lower, 1.6 MPa or lower, or 0.5 MPa or lower. The pressure can be 0.1 to 4.0 MPa, 0.1 to 1.6 MPa, 0.1 to 0.5 MPa, 0.2 to 4.0 MPa, 0.2 to 1.6 MPa, or 0.2 to 0.5 MPa.

[0102] The hydrothermal treatment can be a treatment in which the bagasse is brought into contact with water or steam at a high temperature under high pressure. More specifically, the hydrothermal treatment can be, for example, a method in which the bagasse is brought into contact with water so that the solid concentration of the bagasse becomes 0.1 to 50%, and the decomposition treatment is performed under a high temperature and high pressure. The temperature of the water or steam is preferably 130 to 250°C, and the pressure applied is preferably a pressure that is higher than the saturated water vapor pressure of water at each temperature by 0.1 to 0.5 MPa.

[0103] The acid treatment can be a treatment in which the bagasse is brought into contact with an acidic solution. As the acidic solution, dilute sulfuric acid or the like can be exemplified. The method of bringing the bagasse into contact with the acidic solution, the temperature of the acidic solution in the acid treatment, and the pressure conditions in the acid treatment can be the same as those in the alkali treatment described above.

[0104] The subcritical water treatment can be a treatment in which the bagasse is brought into contact with subcritical water. The method of bringing the bagasse into contact with the subcritical water can be the same as that in the alkali treatment described above. The conditions of the subcritical water treatment are not particularly limited, and it is preferable that the temperature of the subcritical water be set to 160 to 240°C, and the processing time be set to 1 to 90 minutes.

[0105] The explosion treatment can be a treatment in which the insoluble xylan contained in the bagasse is decomposed to a certain extent by the hydrothermal treatment, and then immediately opened by a valve or the like provided on the pressure-resistant reaction vessel, thereby instantaneously releasing to the atmospheric pressure, and thereby pulverizing the bagasse.

[0106] In the decomposition treatment liquid, the above decomposition treatment can be followed by a treatment for separating solid components and liquid components. In this case, the liquid components obtained by the separation can be used as the decomposition treatment liquid. The method for separating the solid components and the liquid components can be separation based on a filter, filtration, centrifugal separation, decantation, or the like.

[0107] In the decomposition treatment liquid, the high molecular components such as polysaccharides can be removed by membrane separation. In this case, the liquid components obtained by the membrane separation can be used as the decomposition treatment liquid. The separation membrane is not particularly limited as long as it is an ultrafiltration membrane (UF membrane). The molecular weight cut-off of the ultrafiltration membrane is preferably 2500 to 50000, more preferably 2500 to 5000.

[0108] As the material of the ultrafiltration membrane, polyimide, polyethersulfone (PES), polysulfone (PS), polyacrylonitrile (PAN), polyvinylidene fluoride (PVDF), regenerated cellulose, cellulose, cellulose ester, sulfonated polysulfone, sulfonated polyethersulfone, polyolefin, polyvinyl alcohol, polymethyl methacrylate, polytetrafluoroethylene, or the like can be used.

[0109] The filtration mode of the ultrafiltration membrane can be dead-end filtration or cross-flow filtration, and from the viewpoint of inhibiting membrane fouling, cross-flow filtration is preferable.

[0110] As the membrane form of the ultrafiltration membrane, a flat membrane type, a spiral type, a tubular type, a hollow fiber type, or the like can be used. More specifically, GE series, GH series, GK series, PW type, HWSUF type of SUEZ, HFM-180, HFM-183, HFM-251, HFM-300, HFK-131, HFK-328, MPT-U20, MPS-U20P, MPS-U20S of KOCH, SPE1, SPE3, SPE5, SPE10, SPE30, SPV5, SPV50, SOW30 of Synder, Microza (registered trademark) UF series of Asahi Chemical Industry Co., Ltd. having a molecular weight cut-off of 3000 to 10000, NTR7410, NTR7450, and the like of Nitto Electric Industrial Co., Ltd. can be listed.

[0111] In other embodiments, the decomposition extract of the bagasse can be a fraction obtained by passing the above decomposition treatment liquid through a column packed with a stationary carrier. By passing the decomposition treatment liquid through the column, the effective components in the decomposition treatment liquid are adsorbed on the stationary carrier, and most of the saccharides and inorganic salts directly flow out.

[0112] The decomposition treatment liquid can be passed through the column directly, or can be adjusted to an arbitrary concentration with water and then passed through the column. The decomposition treatment liquid can be adjusted in pH before being passed through the column. In the case where the stationary carrier is a synthetic adsorbent, the decomposition treatment liquid is preferably adjusted to a pH of 6 or less from the viewpoint of improving the adsorption rate. The pH of the decomposition treatment liquid can be more than 4.5 and 6 or less. In the case where the stationary carrier is an ion exchange resin, the decomposition treatment liquid is preferably adjusted to a pH of 5 or more.

[0113] The stationary carrier is preferably any of a synthetic adsorbent or an ion exchange resin.

[0114] The synthetic adsorbent is preferably a synthetic porous adsorbent. As the synthetic adsorbent (synthetic porous adsorbent), an organic resin can be preferably used. The organic resin is preferably at least one selected from the group consisting of an aromatic resin, an acrylic methacrylic resin, and an acrylonitrile aliphatic resin.

[0115] As the aromatic resin, for example, a styrene-divinylbenzene resin can be exemplified. As the aromatic resin, a porous resin such as an aromatic resin having a hydrophobic substituent, a non-substituted type aromatic resin, a non-substituted type aromatic resin subjected to a special treatment, and the like can be exemplified, of which a non-substituted type aromatic resin or a non-substituted type aromatic resin subjected to a special treatment is preferable.

[0116] As commercially available synthetic adsorbents, the following can be mentioned: Diaion (trademark) HP-10, HP-20, HP-21, HP-30, HP-40, HP-50 (all of the above are non-substituted aromatic resins, and are trade names, manufactured by Mitsubishi Chemical Corporation); SP-825, SP-800, SP-850, SP-875, SP-70, SP-700 (all of the above are aromatic resins to which special treatment has been applied to non-substituted types, and are trade names, manufactured by Mitsubishi Chemical Corporation); SP-900 (aromatic resin, trade name, manufactured by Mitsubishi Chemical Corporation); Amberlite (trademark) XAD-2, XAD-4, XAD-16, XAD-2000 (all of the above are aromatic resins, and are trade names, manufactured by Organo Corporation); Diaion (trademark) SP-205, SP-206, SP-207 (all of the above are aromatic resins having hydrophobic substituents, and are trade names, manufactured by Mitsubishi Chemical Corporation); HP-2MG, EX-0021 (all of the above are aromatic resins having hydrophobic substituents, and are trade names, manufactured by Mitsubishi Chemical Corporation); Amberlite (trademark) XAD-7, XAD-8 (all of the above are acrylic resins, and are trade names, manufactured by Organo Corporation); Diaion (trademark) HP1MG, HP2MG (all of the above are acrylic resins, and are trade names, manufactured by Mitsubishi Chemical Corporation); Sephadex (trademark) LH20, LH60 (all of the above are derivatives of crosslinked dextran, and are trade names, manufactured by Pharmacia Biotech, Inc.), and the like. Of these, a non-substituted aromatic resin (for example, HP-20) or an aromatic resin to which special treatment has been applied to a non-substituted type (for example, SP-850) is preferred.

[0117] The amount of the synthetic adsorbent filled in the column can be appropriately determined depending on the size of the column, the kind of the synthetic adsorbent, and the like.

[0118] When the synthetic adsorbent is used as the stationary carrier, the speed at which the decomposition treatment liquid is passed through can be appropriately changed depending on the size of the column, the kind of the elution solvent, the kind of the synthetic adsorbent, and the like, but is preferably SV = 1 to 30 hours -1 . Note that SV (Space Velocity) is a unit of the amount of liquid that passes through per unit of the capacity of the resin per hour.

[0119] The adsorbed component (effective component) adsorbed to the synthetic adsorbent can be eluted by a solvent (elution solvent). From the viewpoint of more efficiently recovering the adsorbed component, before eluting the adsorbed component, it is preferable to flush the sugars and inorganic salts remaining on the column by water washing. In this case, the eluted component can be used as a decomposition extract of bagasse.

[0120] When the synthetic adsorbent is used as the stationary carrier, the elution solvent can be at least one selected from the group consisting of water, methanol, ethanol, and a mixture thereof. The elution solvent is preferably a mixed solvent of alcohol and water, more preferably a mixed solvent of ethanol and water, and further preferably a mixed solvent of ethanol and water having a volume ratio of 50 / 50 to 60 / 40 (ethanol / water) from the viewpoint of more efficiently eluting the adsorbed component at room temperature.

[0121] When the synthetic adsorbent is used as the stationary carrier, the temperature of the column (column temperature) at the time of elution can be room temperature, and by setting the column temperature to a high temperature higher than room temperature, it is possible to reduce the mixing ratio of ethanol in the mixed solvent of ethanol and water, and to more efficiently elute the adsorbed component. The temperature is preferably 20 to 60°C, and more preferably 40 to 60°C. The inside of the column can be under atmospheric pressure or under pressurized conditions.

[0122] When the synthetic adsorbent is used as the stationary carrier, the elution rate can be appropriately set depending on the size of the column, the type of the elution solvent, the type of the synthetic adsorbent, and the like, but is preferably SV = 0.1 to 10 hours -1 .

[0123] Based on the form of the resin, the ion exchange resin can be classified into: a gel-type resin; and a porous resin such as a porous-type, a microporous-type, or a high-porous-type, without particular limitation. The ion exchange resin is preferably a cation exchange resin. As the cation exchange resin, a strong basic cation exchange resin or a weak basic cation exchange resin can be used. When an alkali treatment liquid is used as the raw material, it is preferable to use a strong basic cation exchange resin, but cases where a decomposition treatment liquid based on other treatments is used as the raw material are not particularly limited.

[0124] As commercially available strong basic anion exchange resins, the following can be mentioned: Diaion (trademark) PA306, PA308, PA312, PA316, PA318L, HPA25, SA10A, SA12A, SA11A, SA20A, UBA120 (all manufactured by Mitsubishi Chemical Corporation), Amberlite (trademark) IRA400J, IRA402Bl, IRA404J, IRA900J, IRA904, IRA458RF, IRA958, IRA410J, IRA411, IRA910CT (all manufactured by Organo Corporation), DOWEX (trademark) MARATHON A, MARATHON MSA, MONOSPHERE 550A, MARATHON A2 (all manufactured by Dow Chemical Japan Limited), and the like.

[0125] The amount of the ion exchange resin filled in the column can be appropriately determined depending on the size of the column, the kind of the ion exchange resin, and the like, and is preferably 2 to 10,000 times the wet volume amount, and more preferably 5 to 500 times the wet volume amount, with respect to the solid content of the decomposition treatment liquid.

[0126] The permeation conditions can be appropriately set depending on the kind of the pretreatment liquid, the kind of the ion exchange resin, and the like. It is preferable that the flow rate be SV = 0.3 to 30 hours -1 , the amount of the liquid for permeation be 100 to 300% by volume of the ion exchange resin, and the column temperature be 40 to 90°C. The inside of the column can be under normal pressure or under pressurized conditions.

[0127] When the ion exchange resin is used as the stationary carrier, the decomposition extract of the bagasse can be a fraction obtained by eluting, with an eluent such as an aqueous solution of a salt, an acid, an alcohol, or a mixture thereof, through a column filled with the ion exchange resin. In this case, the eluent can be subjected to degassing treatment.

[0128] In one embodiment, the decomposition extract of the bagasse can be a concentrate obtained by concentrating the decomposition treatment liquid or the fraction described above. The method of concentration can be a publicly known method, and for example, a method such as distillation of a solvent under reduced pressure, freeze drying, or the like can be used. When concentration is performed, the decomposition treatment liquid or the fraction can be concentrated to 15 to 30 times, and the component after concentration can be used as the decomposition extract of the bagasse.

[0129] The decomposition extract of sugarcane bagasse can be obtained, for example, as follows. An aqueous solution of sodium hydroxide is added to sugarcane bagasse to give a solid concentration of 0.1 to 50%, and the mixture is boiled at 100°C to obtain a decomposition treatment liquid (alkali treatment liquid). The decomposition treatment liquid is subjected to ultrafiltration using a UF membrane having a molecular weight cut-off of 2500 to 5000, and the obtained filtrate is adjusted to be acidic. The filtrate is then passed through a column packed with an unsubstituted aromatic resin at a column temperature of 20 to 60°C. Then, the components adsorbed to the column are eluted with a mixed solvent (elution solvent) of ethanol and water at a volume ratio of 50 / 50 to 60 / 40 (ethanol / water) at a column temperature of 20 to 60°C, and the fraction collected from the time when elution with the mixed solvent of ethanol and water is started until the amount of the eluate collected is 45 times the wet volume of the aromatic resin is recovered. The recovered fraction (a fraction containing components having a bone metabolism improving effect) is concentrated by a conventional means (solvent distillation under reduced pressure, freeze drying, etc.), whereby a decomposition extract of sugarcane bagasse can be obtained. The decomposition extract of sugarcane bagasse thus obtained can be stored in a liquid state concentrated to a solid content of 30% by mass or more or in the form of a powdered extract. When the extract is in a liquid state, the storage of the extract is preferably performed by refrigeration.

[0130] As another example, the decomposition extract of sugarcane bagasse can be obtained, for example, as follows. That is, water is added to sugarcane bagasse to give a solid concentration of 0.1 to 50%, and the mixture is subjected to hydrothermal treatment at a temperature of 130 to 250°C under a pressure of 0.2 to 4.0 MPa, and a decomposition treatment liquid (hydrothermal treatment liquid) is obtained by solid-liquid separation based on filtration. The obtained hydrothermal treatment liquid is passed through a column packed with an unsubstituted aromatic resin subjected to special treatment at a temperature of 20 to 60°C, and then the components adsorbed to the column are eluted with a mixed solvent (elution solvent) of ethanol and water at a volume ratio of 50 / 50 to 60 / 40 (ethanol / water) at a column temperature of 20 to 60°C, and a fraction collected from the time when elution with the mixed solvent of ethanol and water is started until the amount of the eluate collected is 5 times the wet volume of the aromatic resin is recovered. The recovered fraction (a fraction containing components having a bone metabolism improving effect) is concentrated by a conventional means (solvent distillation under reduced pressure, freeze drying, etc.), whereby a decomposition extract of sugarcane bagasse can be obtained. The decomposition extract of sugarcane bagasse thus obtained can be stored in a liquid state concentrated to a solid content of 30% by mass or more or in the form of a powdered extract. When the extract is in a liquid state, the storage of the extract is preferably performed by refrigeration.

[0131] The saccharine bagasse decomposition extract in each of the above embodiments can be in a liquid state or a powder state. The saccharine bagasse decomposition extract in a powder state can be produced, for example, by using a saccharine bagasse decomposition extract in a liquid state and using a spray drying method, a freeze drying method, a fluidized bed granulation method, a powdering method using an excipient, or the like.

[0132] The saccharine bagasse decomposition extract preferably contains at least one selected from the group consisting of p-coumaric acid, ferulic acid, caffeic acid, vanillin, and the like, which are phenylpropanoids, and lignin and decomposition products thereof.

[0133] <1st Embodiment: Obesity Inhibitor>

[0134] The obesity inhibitor in the present specification is a composition having an effect of inhibiting obesity. The effect of inhibiting obesity can be, for example, an effect of inhibiting accumulation of fat in adipocytes (fat accumulation inhibitory effect), an effect of promoting decomposition of fat accumulated in adipocytes (fat decomposition promoting effect), or an effect of inhibiting proliferation of adipocytes (adipocyte proliferation inhibitory effect), or the like. That is, the obesity inhibitor in the present specification can be a fat accumulation inhibitor, a fat decomposition promoter, an adipocyte proliferation inhibitor, or the like.

[0135] The obesity inhibitor of one embodiment contains the saccharine bagasse decomposition extract described above as an effective ingredient.

[0136] The obesity inhibitor of the present embodiment can be composed only of the saccharine bagasse decomposition extract as an effective ingredient, and can further be compounded with a material that can be used for a food, a quasi-drug, or a drug. The material that can be used for a food, a quasi-drug, or a drug is not particularly limited, and examples thereof include amino acids, proteins, carbohydrates, fats and oils, sweeteners, minerals, vitamins, spices, excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, co-solvents, suspending agents, and the like.

[0137] As proteins, for example, casein, whey, soybean protein, wheat protein, egg white, etc. can be exemplified. As carbohydrates, for example, corn starch, cellulose, α- modified starch, wheat starch, rice starch, potato starch, etc. can be exemplified. As oils and fats, for example, salad oil, corn oil, soybean oil, safflower oil, olive oil, palm oil, etc. can be exemplified. As sweeteners, for example, saccharides such as glucose, sucrose, fructose, glucose-fructose syrup, fructose-glucose syrup; sugar alcohols such as xylitol, erythritol, maltitol; artificial sweeteners such as sucralose, aspartame, saccharin, acesulfame K, stevia sweetener, etc. can be exemplified. As minerals, for example, calcium, potassium, phosphorus, sodium, manganese, iron, zinc, magnesium, etc. and their salts, etc. can be exemplified. As vitamins, for example, vitamin E, vitamin C, vitamin A, vitamin D, vitamin B group, biotin, vitamin B3, etc. can be exemplified. As excipients, for example, dextrin, starch, lactose, crystalline cellulose, etc. can be exemplified. As binders, for example, polyvinyl alcohol, gelatin, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, polyvinyl pyrrolidone, etc. can be exemplified. As lubricants, for example, magnesium stearate, calcium stearate, talc, etc. can be exemplified. As disintegrants, for example, crystalline cellulose, xylitol, gelatin, calcium carbonate, sodium bicarbonate, dextrin, etc. can be exemplified. As emulsifiers or surfactants, for example, sucrose fatty acid ester, citric acid, lactic acid, glycerin fatty acid ester, polyglycerin fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, lecithin, etc. can be exemplified. As bases, for example, cetyl octadecanol, lanolin, polyethylene glycol, etc. can be exemplified. As co-solvents, for example, polyethylene glycol, propylene glycol, sodium carbonate, sodium citrate, etc. can be exemplified. As suspending agents, for example, glycerin monostearate, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxymethyl cellulose, sodium alginate, etc. can be exemplified. These can be used singly or in combination of two or more.

[0138] In the case where other materials are compounded in the obesity inhibitor, the content of the decomposed extract of sugarcane bagasse as the effective ingredient can be appropriately set according to the form of the obesity inhibitor, the purpose of use, etc. to be described later, but from the viewpoint of further easily inhibiting the accumulation of fat in fat cells, it is preferably 100 μg / g or more, more preferably 250 μg / g or more, further preferably 400 μg / g or more, and on the other hand, it is preferably 10 mg / g or less, more preferably 7.5 mg / g or less, further preferably 5 mg / g or less, based on the total amount of the obesity inhibitor.

[0139] The obesity inhibitor can be in any shape of a solid (powder, granules, etc.), a liquid (solution, suspension, etc.), a paste, etc., and can be in any dosage form of a powder, a pill, granules, a tablet, a capsule, a lozenge, a liquid preparation, a suspension, etc.

[0140] One of the mechanisms of obesity is that adipocytes synthesize fat and accumulate fat and hypertrophy. The obesity inhibitor of the present embodiment has an effect of inhibiting the accumulation of fat in adipocytes, in particular. Therefore, by ingesting the obesity inhibitor of the present embodiment, the accumulation of fat in adipocytes can be inhibited, and as a result, obesity can be inhibited. According to the obesity inhibitor, obesity can be effectively inhibited or eliminated without relying on excessive exercise, dietary restriction, and thus is useful.

[0141] Whether the obesity inhibitor has an effect of inhibiting fat accumulation can be confirmed, for example, by staining fat droplets accumulated when fat precursor cells are induced to differentiate into adipocytes with lipophilic pigment and performing microscopic observation, and observing whether the fat droplets of a test subject to which the fat inhibitor has been added are reduced compared to a test subject to which the fat inhibitor has not been added, and thereby confirming. In addition, whether the obesity inhibitor has an effect of inhibiting fat accumulation can also be confirmed by extracting the lipophilic pigment that stains the fat droplets and measuring the absorbance, calculating the degree of fat accumulation from the change in absorbance with the addition of the fat inhibitor, and thereby confirming.

[0142] The obesity inhibitor can be used as a food, quasi-drug, or drug. The food can also be provided, for example, in the form of a health food, a specified health food, a functional food, a nutritionally functional food, a nutritional supplement, or the like.

[0143] The obesity inhibitor can be administered parenterally such as intravenously, and can also be administered orally. The obesity inhibitor is preferably administered orally.

[0144] In the case of non-oral administration of the obesity suppressor, as the amount of administration, the decomposed extract of sugar cane bagasse is preferably administered so as to be 50 μg / kg (body weight) or more per time, more preferably 150 μg / kg (body weight) or more, and further preferably 250 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 100 μg / kg (body weight) or more per day, more preferably 300 μg / kg (body weight) or more, and further preferably 500 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 2000 mg / kg (body weight) or less per time, more preferably 1500 mg / kg (body weight) or less, and further preferably 1000 mg / kg (body weight) or less. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 4000 mg / kg (body weight) or less per day, more preferably 3000 mg / kg (body weight) or less, and further preferably 2000 mg / kg (body weight) or less. If it is within this range, a sufficient blood concentration can be achieved, and the effect of suppressing obesity can be more favorably exhibited.

[0145] In the case of oral administration of the obesity suppressor, as the amount of administration, the decomposed extract of sugar cane bagasse is preferably administered so as to be 60 μg / kg (body weight) or more per time, more preferably 120 μg / kg (body weight) or more, and further preferably 180 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 180 μg / kg (body weight) or more per day, more preferably 360 μg / kg (body weight) or more, and further preferably 540 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 1000 mg / kg (body weight) or less per time, more preferably 800 mg / kg (body weight) or less, and further preferably 600 mg / kg (body weight) or less. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 3000 mg / kg (body weight) or less per day, more preferably 2000 mg / kg (body weight) or less, and further preferably 1000 mg / kg (body weight) or less. If it is within this range, a sufficient blood concentration can be achieved, and the effect of suppressing obesity can be more favorably exhibited.

[0146] The obesity inhibitor of the present embodiment has the above-mentioned effects, and thus can be used for a patient diagnosed with obesity and for a standard weight person who wishes to prevent obesity.

[0147] The specific mode of the fat accumulation inhibitor of one embodiment can be the same as that of the obesity inhibitor described above. That is, for the fat accumulation inhibitor of one embodiment, in the description regarding the obesity inhibitor described above, "obesity inhibitor" can be understood as "fat accumulation inhibitor".

[0148] One embodiment of the present application can be considered as a method for inhibiting obesity or fat accumulation, which includes a step of administering an effective amount of an obesity inhibitor or fat accumulation inhibitor containing the above-mentioned decomposition extract of bagasse as an effective ingredient to a subject in need thereof. In addition, one embodiment of the present application can be considered as a decomposition extract of bagasse for use in a method for inhibiting obesity or fat accumulation. The subject in the above-mentioned method can be a mammal, preferably a human. The mode of the obesity inhibitor or fat accumulation inhibitor, the method of administration, the amount of administration (intake amount), and the like are the same as in the above-mentioned cases.

[0149] Another embodiment of the present application can also be considered as an application of a decomposition extract of bagasse for the production of an obesity inhibitor or fat accumulation inhibitor. In addition, one embodiment of the present application can also be considered as an application of a decomposition extract of bagasse for use in the inhibition of obesity or fat accumulation. The mode of the obesity inhibitor or fat accumulation inhibitor is the same as in the above-mentioned cases.

[0150] <2nd Embodiment: Anti-dementia Agent>

[0151] The anti-dementia agent of the present application has an anti-dementia effect. The concept of "anti-dementia effect" in the present application includes an effect of preventing the onset of dementia, an effect of delaying the onset of dementia, and an effect of recovering dementia once developed from the state at the time of onset. The dementia targeted by the anti-dementia agent of the present application can be Alzheimer's type dementia. Alzheimer's type dementia has a condition caused by the loss of acetylcholinergic nerve cells in the brain of the brain's basal portion, the substantia innominata (cholinergic hypothesis), and a condition caused by the accumulation of β-amyloid protein (amyloid hypothesis). These two show different conditions and the same condition is not observed from different perspectives. The dementia targeted by the anti-dementia agent of the present application can be Alzheimer's type dementia based on any hypothesis, and is preferably Alzheimer's type dementia based on the amyloid hypothesis. That is, the dementia targeted by the anti-dementia agent of the present application can be Alzheimer's type dementia caused by the accumulation of β-amyloid protein. In other words, the present application can also provide an anti-dementia agent for Alzheimer's type dementia, an anti-dementia agent for Alzheimer's type dementia based on the amyloid hypothesis, or an anti-dementia agent for Alzheimer's type dementia caused by the accumulation of β-amyloid protein.

[0152] In Alzheimer's type dementia based on the amyloid hypothesis, in addition to β-amyloid protein, the accumulation of tau protein in the brain causes the death of brain nerve cells, and it is believed that cognitive function is impaired. β-amyloid protein begins to accumulate at the initial stage, and tau protein begins to accumulate about 10 years later. It is said that brain nerve cells die due to the continuous accumulation of β-amyloid protein and tau protein, and dementia develops about 25 years after the initial stage. In another aspect, the anti-dementia agent of the present application can also have an effect of inhibiting the accumulation of β-amyloid protein in the brain, an effect of reducing the accumulation of β-amyloid protein in the brain, and an effect of inhibiting the accumulation of tau protein in the brain, an effect of reducing the accumulation of tau protein in the brain.

[0153] The present application can also provide a memory disorder improving / inhibiting agent. The memory disorder improving / inhibiting agent of the present application has an effect of improving / inhibiting a memory disorder. The concept of "improving / inhibiting a memory disorder" in the present application includes an effect of preventing the onset of a memory disorder, an effect of delaying the onset of a memory disorder, and an effect of recovering a memory disorder once developed from the state at the time of onset. The memory disorder targeted by the memory disorder improving / inhibiting agent of the present application can be a long-term memory disorder or a short-term memory disorder, but is preferably a short-term memory disorder. That is, the present application can provide a short-term memory disorder improving / inhibiting agent, and further can provide an improving / inhibiting agent for a short-term memory disorder caused by the accumulation of β-amyloid protein.

[0154] The anti-dementia agent of one embodiment contains the above-described decomposed extract of bagasse as an effective ingredient.

[0155] The anti-dementia agent can be composed only of the decomposed extract of bagasse as an effective ingredient, and can further be compounded with a material that can be used for a food, quasi-drug, or drug. The material that can be used for a food, quasi-drug, or drug is not particularly limited, and examples thereof include an amino acid, a protein, a carbohydrate, a fat, a sweetening agent, a mineral, a vitamin, a flavoring agent, an excipient, a binder, a lubricant, a disintegrant, an emulsifying agent, a surfactant, a base, a co-solvent, a suspending agent, and the like. As the protein, carbohydrate, fat, sweetening agent, mineral, vitamin, flavoring agent, excipient, binder, lubricant, disintegrant, emulsifying agent, surfactant, base, co-solvent, and suspending agent, the same materials as those used in the above-described obesity inhibitor can be used.

[0156] In the case where the anti-dementia agent is compounded with other materials, the content of the decomposed extract of bagasse as an effective ingredient is appropriately set according to the form of the anti-dementia agent, the purpose of use, and the like described later, and is preferably in the following range based on the total amount of the anti-dementia agent from the viewpoint of more effectively exerting the anti-dementia effect. As the content of the decomposed extract of bagasse, it is preferable that the solid content other than monosaccharides and oligosaccharides be 1% by mass or more, more preferably 3% by mass or more, and further preferably 5% by mass or more, and it is also preferable that the solid content be 50% by mass or less, more preferably 40% by mass or less, and further preferably 30% by mass or less.

[0157] The anti-dementia agent can be used as a food, quasi-drug, or drug. The food can be provided in the form of a health food, a specified health food, a functional food, a nutritionally functional food, a nutritional supplement, or the like.

[0158] The anti-dementia agent can also be used as a feed, feed additive. As the feed, examples include a companion animal feed such as dog food and cat food, a livestock feed, a poultry feed, a feed for cultured seafood, and the like. The "feed" includes all foods that are taken orally by animals for nutritional purposes. More specifically, when classified from the viewpoint of the content of nutritional ingredients, all of roughage, concentrated feed, inorganic feed, and special feed are included, and when classified from the viewpoint of official standards, all of compounded feed, mixed feed, and single feed are included. Further, when classified from the viewpoint of the feeding method, all of feed that is directly fed, feed that is mixed with other feed and fed, or feed that is added to drinking water to supplement nutritional ingredients is included.

[0159] The anti-dementia agent can be in any shape such as a solid (powder, granules, and the like), a liquid (solution, suspension, and the like), and a paste, and can be in any dosage form such as a powder, a pill, a granule, a tablet, a capsule, a lozenge, a liquid preparation, a suspension, and the like.

[0160] The anti-dementia agent can be administered parenterally such as intravenously, and can also be administered orally. The anti-dementia agent is preferably administered orally.

[0161] In the case of parenteral administration of the anti-dementia agent, as the amount of administration, the decomposed extract of sugar cane bagasse is preferably administered so as to be 100 μg / kg (body weight) or more per administration, more preferably 150 μg / kg (body weight) or more, and further preferably 200 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 200 μg / kg (body weight) or more per day, more preferably 300 μg / kg (body weight) or more, and further preferably 400 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 2000 mg / kg (body weight) or less per administration, more preferably 1500 mg / kg (body weight) or less, and further preferably 1000 mg / kg (body weight) or less. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 4000 mg / kg (body weight) or less per day, more preferably 3000 mg / kg (body weight) or less, and further preferably 2000 mg / kg (body weight) or less. If the range is within this range, a sufficient blood concentration can be achieved, and the anti-dementia effect can be more favorably exhibited.

[0162] In the case of oral administration of the anti-dementia agent, when the above preparation containing the anti-dementia agent is taken in a lump, the amount of the above preparation taken (the amount taken per day or the amount administered) is preferably 50 to 3000 mg / kg (body weight), and more preferably 100 to 2000 mg / kg (body weight), based on the total amount of the decomposed extract of sugar cane bagasse other than monosaccharides and oligosaccharides (solid content). When taken for a long period of time on a daily basis, the amount of the above preparation taken (the amount taken per day) is preferably 1 to 1000 mg / kg (body weight), based on the total amount of the decomposed extract of sugar cane bagasse other than monosaccharides and oligosaccharides (solid content).

[0163] The anti-dementia agent of the present embodiment can be used for a human or an animal in which β-amyloid protein is accumulated. In addition, the anti-dementia agent of the present embodiment can be used for a human or an animal having dementia (or Alzheimer's type dementia), or a human or an animal having memory disorder (or short-term memory disorder). It is considered that the dementia and the memory disorder are caused by accumulation of β-amyloid protein.

[0164] The specific means of the short-term memory disorder improving / inhibiting agent of one embodiment can be the same as that of the anti-dementia agent described above. That is, for the short-term memory disorder improving / inhibiting agent of one embodiment, in the description regarding the anti-dementia agent described above, "anti-dementia agent" can be understood as "short-term memory disorder improving / inhibiting agent".

[0165] One embodiment of the present application can also be considered as a method for improving / inhibiting dementia or short-term memory disorder, which includes a step of administering an effective amount of an anti-dementia agent or a short-term memory disorder improving / inhibiting agent containing the decomposition extract of sugar cane bagasse described above as an effective ingredient to a subject in need thereof. In addition, one embodiment of the present application can be considered as a decomposition extract of sugar cane bagasse for a method for improving / inhibiting dementia or short-term memory disorder. The subject in the above method can be a mammal, preferably a human. The means of the anti-dementia agent or the short-term memory disorder improving / inhibiting agent, the method of administration, the amount of administration (intake amount), and the like are the same as in the above cases.

[0166] Another embodiment of the present application can also be considered as an application of a decomposition extract of sugar cane bagasse for manufacturing an anti-dementia agent or a short-term memory disorder improving / inhibiting agent. In addition, one embodiment of the present application can also be considered as an application of a decomposition extract of sugar cane bagasse for improving / inhibiting dementia or short-term memory disorder. The means of the anti-dementia agent or the short-term memory disorder improving / inhibiting agent are the same as in the above cases.

[0167] <3rd Embodiment: Deodorant>

[0168] The "deodorant" in the present specification contains a component having a deodorizing effect (effective ingredient). The deodorant can be a deodorant that exerts a deodorizing effect by removing or inhibiting the odor of a deodorizing object, and can also be a deodorant (masking agent) that exerts a deodorizing effect by masking the odor of a deodorizing object.

[0169] The deodorant of one embodiment contains the decomposition extract of sugar cane bagasse described above as an effective ingredient. The decomposition extract of sugar cane bagasse contained in the deodorant can be a decomposition-treated liquid obtained by at least one decomposition treatment selected from the group consisting of alkali treatment, hydrothermal treatment, acid treatment, and subcritical water treatment.

[0170] The deodorant of the present embodiment can further contain other components within a range that does not impair the effects brought by the present application. As the other components, for example, other deodorants, perfumes, alcohols, surfactants, antibacterial agents, stabilizing agents, viscosity adjusting agents, pH adjusting agents, preservatives, colorants, and the like can be exemplified.

[0171] The deodorant of the present embodiment can be used as a material for food (food deodorant), a ritual deodorant, a pet deodorant, an environmental deodorant, a detergent, a softener, a hair dye, a perm agent, or a cosmetic. That is, the deodorant can be used for deodorization of an offensive odor generated from a food material such as meat, seafood, leek, garlic, and the like; a body odor (body odor) generated from a human being such as halitosis, underarm odor, foot odor, and the like; an offensive odor attached to hair or a body (grilled meat odor, smoke odor, and the like); an offensive odor generated from an animal such as animal halitosis, body odor, or excrement odor; a malodor generated from a source of household garbage or industrial waste such as a household garbage or industrial waste accumulation site, a household garbage or industrial waste collection site, a household garbage or industrial waste gathering site, a waste recycling site, and the like; an offensive odor in a water pool such as a sewage treatment plant, a urine treatment plant, a crematorium, a livestock breeding farm, a wild animal treatment plant, a hospital, a clinic, a testing center, a washroom, a bathroom, a kitchen, and the like; an offensive odor in a building material and wallpaper (malodor of a treatment agent used in processing such as formalin) in a general indoor environment and indoor building materials and wallpaper; a curtain; a paint; furniture (malodor of a treatment agent such as paint, processing, and the like; mold odor in a closet and the like); a shoe rack; an air conditioner; an interior of an automobile or a truck; a gas generated from an automobile or a truck; an electric train; an airplane; a factory; a restaurant; a photo studio or a developing studio; a gas station; a propane gas supply site; a laundry or a washing factory; a hotel or a restaurant; a beauty parlor or a hair salon; an automobile repair factory; a livestock barn; a construction work site; and the like.

[0172] The deodorant of the present embodiment can be more suitably used for deodorization of an offensive odor with at least one component selected from the group consisting of isovaleric acid, acetic acid, methyl mercaptan, trimethylamine, diacetyl, nonenal, ammonium mercaptoacetate, and monoethanolamine mercaptoacetate as a main component, and a smoke odor. As the offensive odor with the component selected from isovaleric acid, acetic acid, methyl mercaptan, trimethylamine, diacetyl, nonenal, ammonium mercaptoacetate, and monoethanolamine mercaptoacetate as a main component, for example, there can be listed a body odor (including a body odor due to aging) such as sweat, feet, halitosis, and flatulence, an offensive odor of animal excrement, an offensive odor generated from food spoilage or decay, an offensive odor released from a chemical substance used in a building material, wallpaper, furniture, and the like of a building, and the like. As the offensive odor with the component selected from mercaptoacetic acid, a mercaptoacetate salt, cysteine or a derivative thereof, thioglycerol, a sulfite salt, a lactone mercaptan, and cysteamine as a main component, for example, there can be listed an offensive odor of a perm agent containing a reducing agent, and the like.

[0173] The deodorant of the present embodiment can be more suitably used for deodorization of an offensive odor with at least one component selected from the group consisting of isovaleric acid, acetic acid, methyl mercaptan, trimethylamine, diacetyl, nonenal, ammonium mercaptoacetate, and monoethanolamine mercaptoacetate as a main component, and a smoke odor.

[0174] The use form of the deodorant of the present embodiment is not particularly limited. For example, the deodorant of the present embodiment can be used by spraying or coating. As the deodorant used by spraying, there are, for example, aerosol spray type deodorants, spray type deodorants, liquid products for spraying, and the like. The spray type deodorant can be used, for example, for pet odor in the home, a toilet, moisture-containing garbage in the kitchen, cooking utensils, and the like. The deodorant of the present embodiment is added to water, a surfactant, ethanol, an antibacterial agent, and the like are added as necessary, and is filled in a spray bottle to obtain. The aerosol type deodorant can be used, for example, for moisture-containing garbage and toilet odor in the home, which are strong malodors. The aerosol type deodorant is obtained by diluting the deodorant of the present embodiment with water or an aqueous ethanol solution, and filling it in an aerosol container together with a propellant (propellant gas) such as LPG and carbon dioxide. The deodorant used by spraying is dispersed in the room by forming fine mist, and thus deodorization of mainly the room can be performed. In addition, by intermittently or continuously dispersing in places where malodor is likely to occur, such as livestock barns, fish markets, and the like, malodor generated in these places can also be eliminated.

[0175] As the deodorant used by coating, there are, for example, liquid, gel, and paste type deodorants. The liquid, gel, and paste type deodorants can be in the form of a cream, an emulsion, and the like. The deodorant used by coating can be used, for example, for eliminating body odor by coating on the body of a person.

[0176] The deodorant of the present embodiment can be used as a sheet-shaped deodorant immersed in cloth, paper, or nonwoven fabric; a deodorant absorbed into powder or granules; a deodorant kneaded or absorbed into a granular, particulate, block, or tablet-shaped gel (for example, a space deodorant described later); a deodorant absorbed into a porous carrier such as ceramic, activated carbon, bentonite, and the like; a deodorant in which a liquid deodorant is put in a container, a substance having a liquid impregnated with the deodorant in the container, and the deodorant in the container are partially contacted, and the deodorant impregnated with the deodorant gasifies to have a deodorizing effect; a deodorant in which the deodorant is put in a porous container such as ceramic, and the deodorant impregnated to the outside of the container gasifies to have a deodorizing effect; a deodorant added directly to a source of malodor in a liquid state; a deodorant immersed in a film or filter, or wallpaper, building materials, paper diapers, sanitary products, insoles, deodorizing fibers (cloth), or deodorizing leather, and the like, which contain a deodorant on the surface or in the inside.

[0177] The deodorant of the present embodiment can also be used as a space deodorant. A space deodorant gradually volatilizes (disperses) a component (effective component) having a deodorizing effect, and thus long-term deodorizing effect is sustained. A space deodorant is obtained, for example, by adsorbing or kneading the deodorant of the present embodiment into a gel or a suitable carrier. More specifically, a space deodorant can be obtained by adding the deodorant of the present embodiment to one or a combination of two or more of gelling agents (e.g., carrageenan, gellan gum, locust bean gum, polyvinyl alcohol, gum arabic, gellan gum, gelatin, carboxymethyl cellulose, chitin, chitosan, sodium alginate, polyacrylamide), and solidifying, thereby obtaining.

[0178] In addition, the deodorant of the present embodiment can be used to produce a pet excrement treatment agent having a high deodorizing effect. A pet excrement treatment agent can be produced by using bentonite, zeolite, wood powder, paper powder, or the like as a main material, adding sodium polyacrylate, other sodium compounds, magnesium compounds, or the like as needed, adding the deodorant of the present embodiment, adding an appropriate amount of water and mixing, and molding and drying, thereby producing. By placing this in a cat toilet or the like for pets, and by allowing a cat to excrete on the treatment agent, an excrement treatment agent having an excellent deodorizing effect can be obtained.

[0179] In the above-described use modes, the amount of the deodorant of the present embodiment is not particularly limited. In the case of a spray-type deodorant, the content of the deodorant of the present embodiment can be, for example, 0.01 to 50% (volume / volume) based on the total amount of the spray-type deodorant. In the case of an aerosol-type deodorant, the content of the deodorant of the present embodiment can be, for example, 0.2 to 70% (volume / volume) based on the total amount of the aerosol-type deodorant. In the case of a space deodorant, the content of the deodorant of the present embodiment can be, for example, 0.5 to 20% (volume / volume) based on the total amount of the space deodorant.

[0180] By using the method of mixing the deodorant of the present embodiment with other materials, molding, and drying, an article having a deodorizing effect can be obtained. In addition, by mixing two or more materials other than the deodorant of the present embodiment in advance, molding, and drying, and absorbing the deodorant of the present embodiment into the obtained molded product, an article having a deodorizing effect can also be obtained.

[0181] The present application can be considered as a method for producing a deodorant in one embodiment. That is, the method for producing a deodorant includes a step of obtaining a decomposed extract of sugar cane bagasse. The step of obtaining a decomposed extract of sugar cane bagasse can further include a step of subjecting the decomposed extract to at least one decomposition treatment selected from the group consisting of alkali treatment, hydrothermal treatment, acid treatment, and subcritical water treatment in one embodiment. The step of obtaining a decomposed extract of sugar cane bagasse can further include a step of subjecting the decomposed treatment liquid obtained by the decomposition treatment step to fractionation by passing through a column packed with a stationary carrier. The detailed conditions of the decomposition treatment step and the fractionation step are as described above.

[0182] The present application can be considered as a method for producing a deodorant in one embodiment. That is, the method for producing a deodorant includes a step of obtaining a decomposed extract of sugar cane bagasse. The step of obtaining a decomposed extract of sugar cane bagasse can further include a step of subjecting the decomposed extract to at least one decomposition treatment selected from the group consisting of alkali treatment, hydrothermal treatment, acid treatment, and subcritical water treatment in one embodiment. The step of obtaining a decomposed extract of sugar cane bagasse can further include a step of subjecting the decomposed treatment liquid obtained by the decomposition treatment step to fractionation by passing through a column packed with a stationary carrier. The detailed conditions of the decomposition treatment step and the fractionation step are as described above.

[0183] The present application can be considered as a method for producing a deodorant in one embodiment. That is, the method for producing a deodorant includes a step of obtaining a decomposed extract of sugar cane bagasse. The step of obtaining a decomposed extract of sugar cane bagasse can further include a step of subjecting the decomposed extract to at least one decomposition treatment selected from the group consisting of alkali treatment, hydrothermal treatment, acid treatment, and subcritical water treatment in one embodiment. The step of obtaining a decomposed extract of sugar cane bagasse can further include a step of subjecting the decomposed treatment liquid obtained by the decomposition treatment step to fractionation by passing through a column packed with a stationary carrier. The detailed conditions of the decomposition treatment step and the fractionation step are as described above.

[0184] <4th Embodiment: Anti-aging Agent>

[0185] The anti-aging agent of the present application has an anti-aging effect. The anti-aging effect can be an effect of inhibiting aging of the skin, and more specifically, an effect of inhibiting and / or improving reduction in skin function caused by aging, irradiation of ultraviolet rays, or the like. The anti-aging effect can be an effect of inhibiting and / or improving wrinkles, slackening, hardening, or the like of the skin.

[0186] Collagen type I, elastin, hyaluronic acid, and the like contained in the dermis are also referred to as extracellular matrix components. The extracellular matrix components are produced by fibroblasts. One of the causes of aging of the skin is decomposition or reduction of the extracellular matrix components.

[0187] The decomposition of extracellular matrix components is caused by extracellular matrix-degrading enzymes. For example, type I collagen is degraded by matrix metalloproteinase (MMP-1) which is one of the extracellular matrix-degrading enzymes. MMP-1 is increased in amount and enhanced in activity by irradiation of ultraviolet rays. Due to the production and activity enhancement of MMP-1, the collagen is decreased, denatured, or the skin loses elasticity, and can become a cause of formation of wrinkles or slackening of the skin. On the other hand, elastin is degraded by elastase which is one of the extracellular matrix-degrading enzymes. Elastin has a function like a spring that connects between collagen fibers, but the degradation of elastin by elastase also causes the skin to lose elasticity, and can become a cause of formation of wrinkles or slackening of the skin.

[0188] The anti-aging agent of the present application has an action of inhibiting the action of extracellular matrix-degrading enzymes (an action of inhibiting the production of extracellular matrix-degrading enzymes, an action of reducing the activity of extracellular matrix-degrading enzymes), for example, has an action of inhibiting MMP-1 that degrades type I collagen and / or an action of inhibiting elastase that degrades elastin. Thereby, the aging of the skin can be inhibited. That is, the anti-aging agent of the present application can be based on the inhibitory action of extracellular matrix-degrading enzymes, more specifically, can be based on the inhibitory action of MMP-1 or the inhibitory action of elastase. In addition, the present application can provide an extracellular matrix-degrading enzyme inhibitor, more specifically, can provide an MMP-1 inhibitor or an elastase inhibitor.

[0189] The action of inhibiting MMP-1 can be more specifically an action of inhibiting the production of MMP-1, and can be an action of inhibiting the activity of MMP-1. The action of inhibiting elastase can be more specifically an action of inhibiting the production of elastase, and can be an action of inhibiting the activity of elastase. That is, the anti-aging agent of the present application can be based on at least one of the production inhibitory action of MMP-1, the activity inhibitory action of MMP-1, the production inhibitory action of elastase, and the activity inhibitory action of elastase. The anti-aging agent of the present application can be based on the production inhibitory action of MMP-1 and / or the activity inhibitory action of elastase. In addition, the present application can provide an MMP-1 production inhibitor, an MMP-1 activity inhibitor, an elastase production inhibitor, or an elastase activity inhibitor. The present application can also provide an MMP-1 production inhibitor or an elastase activity inhibitor.

[0190] On the other hand, the amount of production of extracellular matrix components decreases due to the decrease in fibroblasts caused by aging, ultraviolet irradiation, or the like. By activating fibroblasts, it is possible to inhibit the decrease in the amount of production of extracellular matrix components. The anti-aging agent of the present application also has the effect of activating fibroblasts, and thus can further inhibit the aging of the skin. That is, the anti-aging agent of the present application can also be based on the activating effect of fibroblasts. In addition, the present application can also provide a fibroblast activator.

[0191] The anti-aging agent of one embodiment contains the above-mentioned decomposed extract of bagasse as an effective component.

[0192] The anti-aging agent can be used as a cosmetic, a food composition, a drug, or a quasi-drug. The food composition can be provided, for example, in the form of a health food, a specific health food, a functional food, a nutritionally functional food, a nutritional supplement, or the like.

[0193] The anti-aging agent can be composed only of the decomposed extract of bagasse as an effective component, and can further be compounded with a material that can be used for a cosmetic, a food composition, a quasi-drug, or a drug. As the material that can be used for a cosmetic, a food composition, a quasi-drug, or a drug, there is no particular limitation, and, for example, amino acids, proteins, carbohydrates, fats, sweeteners, minerals, vitamins, fragrances, excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, co-solvents, suspending agents, and the like can be exemplified. As the proteins, carbohydrates, fats, sweeteners, minerals, vitamins, fragrances, excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, co-solvents, and suspending agents, the same materials as those used in the obesity inhibitor described above can be used.

[0194] In the case where other materials are compounded in the anti-aging agent, the content of the decomposed extract of bagasse as an effective component can be appropriately set depending on the form of the anti-aging agent, the purpose of use, or the like described later, and, from the viewpoint of further effectively exerting the anti-aging effect, it is preferably in the range described below on the basis of the total amount of the anti-aging agent. The content of the decomposed extract of bagasse is preferably 0.5% by mass or more, more preferably 1% by mass or more, and further preferably 3% by mass or more, in terms of solid components, and is preferably 50% by mass or less, more preferably 40% by mass or less, and further preferably 30% by mass or less.

[0195] The shape of the anti-aging agent is not limited, and can be any of a solid (powder, granules, or the like), a liquid (solution, suspension, or the like), a paste, or the like, and can be any of a dosage form such as a powder, a pill, granules, a tablet, a capsule, a lozenge, a liquid preparation, a suspension, or the like.

[0196] In the case where the anti-aging agent is used as a cosmetic, the cosmetic can be a base cosmetic such as a cosmetic water, emulsion, lotion, cream, beauty liquid, oil, pack, lip balm, etc., a hair styling material such as a hair conditioner, hair styling liquid, etc., a hair cosmetic such as a hair growth material, hair nourishing material, etc., a makeup cosmetic such as a foundation, lipstick, blush, eye shadow, eyeliner, mascara, eyebrow pencil, etc.

[0197] The anti-aging agent can be administered orally, and can also be administered non-orally.

[0198] In the case where the anti-aging agent is administered orally, as the amount of administration, for example, the decomposed extract of sugar cane bagasse is preferably administered so as to be 50 μg / kg (body weight) or more per time, more preferably so as to be 100 μg / kg (body weight) or more, and further preferably so as to be 150 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 150 μg / kg (body weight) or more per day, more preferably so as to be 300 μg / kg (body weight) or more, and further preferably so as to be 450 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 1000 mg / kg (body weight) or less per time, more preferably so as to be 800 mg / kg (body weight) or less, and further preferably so as to be 600 mg / kg (body weight) or less. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 3000 mg / kg (body weight) or less per day, more preferably so as to be 2000 mg / kg (body weight) or less, and further preferably so as to be 1000 mg / kg (body weight) or less. If it is within this range, the anti-aging agent can act on the dermis at a sufficient concentration, and the anti-aging effect can be more favorably exhibited.

[0199] In the case where the anti-aging agent is administered non-orally to the skin, as the amount of administration to the skin, for example, the decomposed extract of sugar cane bagasse is preferably administered so as to be 5 μg / cm 2 is administered in the above manner, more preferably so as to be 10 μg / cm 2 is administered in the above manner, further preferably so as to be 30 μg / cm 2 is administered in the above manner. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 10 μg / cm 2 is administered in the above manner, more preferably so as to be 20 μg / cm 2 is administered in the above manner, further preferably so as to be 60 μg / cm 2 is administered in the above manner. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 500 μg / cm 2The following is applied, more preferably to become 400 μg / cm 2 The following is applied, further preferably to become 300 μg / cm 2 The following is applied. In addition, the decomposed extract of sugarcane bagasse is preferably applied to become 1000 μg / cm per day 2 The following is applied, more preferably to become 800 μg / cm 2 The following is applied, further preferably to become 600 μg / cm 2 The following is applied. If it is in this range, it is possible to make the anti-aging agent act on the dermis at a sufficient concentration, and it is possible to more favorably exhibit an anti-aging effect.

[0200] The anti-aging agent can also be used as a feed, a feed additive. As the feed, there can be listed a feed for companion animals such as dog food, cat food, a feed for livestock, a feed for poultry, a feed for cultured seafood, and the like. The "feed" includes all foods that are taken orally by animals for nutritional purposes. More specifically, when classified from the viewpoint of the content of nutritional ingredients, all of roughage, concentrated feed, inorganic feed, and special feed are included, and in addition, when classified from the viewpoint of official standards, all of compounded feed, mixed feed, and single feed are included. In addition, when classified from the viewpoint of the feeding method, all of feed that is directly fed, feed that is mixed with other feed and fed, or feed that is added to drinking water for supplementing nutritional ingredients are included.

[0201] The specific mode of the extracellular matrix-degrading enzyme inhibitor or fibroblast activator of one embodiment can be the same as that of the anti-aging agent described above. That is, the extracellular matrix-degrading enzyme inhibitor or fibroblast activator of one embodiment can be understood as "anti-aging agent" in the description regarding the anti-aging agent described above.

[0202] One embodiment of the present application can also be considered as an anti-aging method, a method of inhibiting an extracellular matrix-degrading enzyme, or a method of activating fibroblasts, the methods including the step of administering an effective amount of an anti-aging agent, an extracellular matrix-degrading enzyme inhibitor, or a fibroblast activator containing the above-described decomposed extract of sugarcane bagasse as an effective ingredient to a subject in need thereof. In addition, one embodiment of the present application can be considered as a decomposed extract of sugarcane bagasse for use in an anti-aging method, a method of inhibiting an extracellular matrix-degrading enzyme, or a method of activating fibroblasts. The subject in the above-described methods can be a mammal, preferably a human. The mode, the method of administration, the amount of administration (intake amount), and the like of the anti-aging agent, the extracellular matrix-degrading enzyme inhibitor, or the fibroblast activator are the same as described above.

[0203] Another embodiment of the present invention can also be considered as the use of a decomposition extract of sugarcane bagasse for the production of an anti-aging agent, an extracellular matrix degrading enzyme inhibitor, or a fibroblast activator. Furthermore, another embodiment of the present invention can also be considered as the use of a decomposition extract of sugarcane bagasse for anti-aging, for inhibiting extracellular matrix degrading enzymes, or for activating fibroblasts. The form, administration method, and dosage (ingestion amount) of the anti-aging agent, extracellular matrix degrading enzyme inhibitor, or fibroblast activator are the same as those described above.

[0204] <Fifth embodiment: Anti-glycation agent>

[0205] The anti-glycation agent herein has anti-glycation activity, specifically, it may have an inhibitory effect on the production (glycation reaction inhibitory effect), accumulation inhibition, or degradation of advanced glycation end products (AGEs). In other words, the anti-glycation agent of this embodiment may be, for example, an inhibitor of the production (glycation reaction inhibitor), accumulation inhibition, or degradation agent (decomposition promoter) of advanced glycation end products.

[0206] The final saccharification product (final saccharification product) is a general term for products obtained by saccharification reaction (Maillard reaction). Examples of the final saccharification product include: ε -(Carboxymethyl)lysine (CML(N ε -carboxymethyl)lysine), pentosidine, pyrraline, and crossline. Furthermore, the anti-glycation agent of this embodiment can exhibit the aforementioned anti-glycation activity by inhibiting the formation, accumulation, or degradation of reaction intermediates in the glycation reaction. Specifically, reaction intermediates in the glycation reaction include glyoxal (GO), 3-deoxyglucose ketone aldehyde (3DG), and methylglyoxal (MGO).

[0207] The anti-glycation agent of the present embodiment contains the above-mentioned decomposed extract of bagasse as an active ingredient.

[0208] The content of the decomposed extract of bagasse in the anti-glycation agent may be 0.01 to 100% by mass, or 0.1 to 100% by mass, based on the total amount of the anti-glycation agent.

[0209] The anti-glycation agent of the present embodiment can contain an excipient or the like in addition to the decomposition extract of sugar cane residue. As the excipient, in the case of the anti-glycation agent for animals, there can be mentioned various starches such as corn starch and wheat starch, dextrin, various gluten, wheat flour, bran, various rice bran such as defatted rice bran, soybean residue, soybean meal, sugars such as glucose and lactose, oils and fats such as vegetable oil and animal oil, fish meal, yeast, silicon compounds, various phosphates, minerals such as diatomaceous earth and bentonite, and the like, which can be used in the preparation of feed and feed additive preparations. In addition, as the excipient, in the case of the anti-glycation agent for humans, there can be mentioned sugars such as lactose, starch, and maltose, which can be used in the preparation of preparations for other humans. Among these, corn starch, dextrin, and defatted rice bran can be used as a carrier for preparations, and by mixing them with the decomposition extract of sugar cane residue, it is possible to produce the anti-glycation agent as a solid preparation such as a powder, granules, or tablets.

[0210] The anti-glycation agent of the present embodiment can exert an anti-glycation effect by being administered to a human or an animal (orally or non-orally).

[0211] In the case of non-oral administration of the anti-glycation agent, as the amount of administration, for example, the decomposition extract of sugar cane residue is preferably administered so as to be 100 μg or more per 1 kg of body weight at a time, more preferably so as to be 150 μg or more, and further preferably so as to be 200 μg or more. In addition, the decomposition extract of sugar cane residue is preferably administered so as to be 200 μg or more per 1 kg of body weight per day, more preferably so as to be 300 μg or more, and further preferably so as to be 400 μg or more. In addition, the decomposition extract of sugar cane residue is preferably administered so as to be 2000 mg or less per 1 kg of body weight at a time, more preferably so as to be 1500 mg or less, and further preferably so as to be 1000 mg or less. In addition, the decomposition extract of sugar cane residue is preferably administered so as to be 4000 mg or less per 1 kg of body weight per day, more preferably so as to be 3000 mg or less, and further preferably so as to be 2000 mg or less. If it is within this range, a sufficient blood concentration can be achieved, and the anti-glycation activity can be more favorably exhibited.

[0212] In the case of oral administration of the anti-glycation agent, the amount of the anti-glycation agent to be administered can be appropriately determined depending on the degree of purification, the form of the decomposition extract of bagasse, the kind of the animal to be the subject, the health condition, the degree of growth, and the like. In determining the amount to be administered, the form of administration, for example, either of concentrated administration or long-term administration, is an important factor. In the case of concentrated administration, the amount of the anti-glycation agent to be administered can be 50 to 3000 mg or 100 to 2000 mg per 1 kg of body weight per day based on the total amount of the decomposition extract of bagasse (solid content). In addition, the administration period in the case of concentrated administration can be 1 to 20 days. In the case of daily long-term administration, the amount of the anti-glycation agent to be administered can be 1 to 500 mg or 1 to 100 mg per 1 kg of body weight per day based on the total amount of the decomposition extract of bagasse (solid content). The administration period in the case of long-term administration can be, for example, several weeks to several months (for example, 20 to 180 days). If it is within this range, a sufficient blood concentration can be achieved, and the anti-glycation activity can be more favorably exhibited.

[0213] The anti-glycation agent of the present embodiment can be used as a component of a product such as a medicine, a quasi-drug, a food or drink (food composition), a feed, a feed additive, and the like. As a food or drink (beverage and food), for example, a health food, a functional food, a food for special dietary uses, a nutritionally supplemented food, a nutritionally enriched food, a food for specified health use, and the like can be exemplified. In addition, the above-described anti-glycation agent can also be used as a component in a seasoning (soy sauce, miso, and the like), a snack, and the like, or a beverage such as water, a refreshing beverage, a fruit juice beverage, an alcoholic beverage, and the like.

[0214] As a feed, a companion animal feed such as dog food, cat food, a livestock feed, a poultry feed, a feed for cultured seafood, and the like can be exemplified. The "feed" includes all foods that are taken orally by an animal for nutritional purposes. Specifically, when classified from the viewpoint of the content of nutritional components, all of roughage, concentrated feed, inorganic feed, and special feed are included, and when classified from the viewpoint of official standards, all of compounded feed, mixed feed, and single feed are included. In addition, when classified from the viewpoint of the feeding method, all of feed that is directly fed, feed that is mixed with other feed and fed, or feed that is added to drinking water for supplementing nutritional components are included.

[0215] The above-described product (for example, a food or drink) composed of or containing the anti-glycation agent of the present embodiment can be for anti-glycation. That is, the food or drink containing the anti-glycation agent of the present embodiment can be favorably used as an anti-glycation food or drink or an anti-glycation food composition. The shape of the above-described product containing the anti-glycation agent can be any of a solid or a liquid.

[0216] The content of the anti-glycation agent contained in the above-mentioned product can be appropriately determined depending on the kind of the above-mentioned product and the intake method. From the viewpoint of more effectively exerting the anti-glycation effect, the above-mentioned product preferably contains the decomposed extract of sugar cane bagasse in an amount of 0.001% by mass or more based on the solid content. When the above-mentioned product containing the anti-glycation agent is taken in a concentrated manner, the intake amount of the above-mentioned product (intake amount per day) is preferably 50 to 3000 mg / kg (body weight) based on the total amount of the decomposed extract of sugar cane bagasse (solid content), and more preferably 100 to 2000 mg / kg (body weight). When long-term intake is performed on a daily basis, the intake amount of the above-mentioned product (intake amount per day) is preferably 1 to 500 mg / kg (body weight) based on the total amount of the decomposed extract of sugar cane bagasse (solid content).

[0217] One embodiment of the present application can also be considered as an anti-glycation method including the step of administering an effective amount of an anti-glycation agent containing the above-mentioned decomposed extract of sugar cane bagasse as an effective ingredient to a subject in need thereof. In addition, one embodiment of the present application can be considered as the decomposed extract of sugar cane bagasse for use in an anti-glycation method. The subject in the above-mentioned method can be a mammal, and preferably a human. The form of the anti-glycation agent, the administration method, the administration amount (intake amount), and the like are the same as in the above-mentioned cases.

[0218] Another embodiment of the present application can also be considered as the use of the decomposed extract of sugar cane bagasse for the production of an anti-glycation agent. In addition, one embodiment of the present application can also be considered as the use of the decomposed extract of sugar cane bagasse for anti-glycation. The form of the anti-glycation agent, the administration method, the administration amount (intake amount), and the like are the same as in the above-mentioned cases.

[0219] <6th Embodiment: Anti-Type I Allergy Agent>

[0220] The anti-type I allergy agent in the present specification is a composition having an action of inhibiting the symptoms of type I allergy. The action of inhibiting the symptoms of type I allergy can be an action of alleviating, treating, or preventing the symptoms caused by type I allergy such as pollinosis, urticaria, allergic rhinitis, bronchial asthma, and the like. In addition, the action of inhibiting the symptoms of type I allergy can be an action of inhibiting the degranulation of mast cells or basophils in the mechanism of type I allergy. That is, the anti-type I allergy agent in the present specification can be a degranulation inhibitor of mast cells or basophils.

[0221] The anti-type I allergy agent of one embodiment contains the decomposed extract of sugar cane bagasse as an effective ingredient.

[0222] The anti-type I allergy agent of the present embodiment can be composed only of the decomposition extract of sugar cane residue as an effective component, and can further be compounded with a material that can be used for a food, quasi-drug, or drug. The material that can be used for a food, quasi-drug, or drug is not particularly limited, and for example, amino acids, proteins, carbohydrates, fats, sweeteners, minerals, vitamins, spices, excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, co-solvents, suspending agents, and the like can be exemplified. As the proteins, carbohydrates, fats, sweeteners, minerals, vitamins, spices, excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, co-solvents, and suspending agents, the same materials as those used in the obesity inhibitor described above can be used.

[0223] In the case where the anti-type I allergy agent is compounded with other materials, the content of the decomposition extract of sugar cane residue as an effective component can be appropriately set depending on the form of the anti-type I allergy agent, the purpose of use, and the like described later, and from the viewpoint of further inhibiting the degranulation of adipocytes or basophils, it is preferably 100 μg / g or more, more preferably 25 μg / g or more, and further preferably 400 μg / g or more, based on the total amount of the anti-type I allergy agent, and is preferably 10 mg / g or less, more preferably 7.5 mg / g or less, and further preferably 5 mg / g or less.

[0224] The anti-type I allergy agent can be in any shape of a solid (powder, granules, and the like), a liquid (solution, suspension, and the like), a paste, and the like, and can be in any dosage form of a powder, a pill, granules, a tablet, a capsule, a lozenge, a liquid preparation, a suspension, and the like.

[0225] The anti-type I allergy agent of the present embodiment has an effect of inhibiting the release of granules containing chemical mediators such as histamine and leukotrienes from adipocytes or basophils to the outside of cells (degranulation) in a type I allergy reaction (degranulation inhibitory effect). Therefore, according to the anti-type I allergy agent of the present embodiment, it is possible to effectively inhibit, treat, or prevent a symptom caused by a type I allergy reaction.

[0226] Whether the anti-type I allergy agent has a degranulation inhibitory effect can be confirmed, for example, by using a cell such as a rat basophilic leukemia cell (RBL-2H3 cell) that releases granulocytes containing histamine and the like to the outside of the cell by cross-linking of IgE bound to the cell surface with an antigen, and calculating to what extent the degranulation of the test subject to which the anti-type I allergy agent is added is inhibited compared with the test subject to which the anti-type I allergy agent is not added, when the cell is stimulated by the antigen.

[0227] The anti-type I allergy agent can be used as a food, quasi-drug, or drug. The food can be provided, for example, as a health food, a specific health food, a functional food, a nutritionally functional food, a nutritional supplement, or the like.

[0228] The anti-type I allergy agent can be administered parenterally, such as intravenously, and can also be administered orally. The anti-type I allergy agent is preferably administered orally.

[0229] In the case of parenteral administration of the anti-type I allergy agent, the saccharum officinarum bagasse decomposition extract is preferably administered so as to be 50 μg / kg (body weight) or more per administration, more preferably 150 μg / kg (body weight) or more, and further preferably 250 μg / kg (body weight) or more. In addition, the saccharum officinarum bagasse decomposition extract is preferably administered so as to be 100 μg / kg (body weight) or more per day, more preferably 300 μg / kg (body weight) or more, and further preferably 500 μg / kg (body weight) or more. In addition, the saccharum officinarum bagasse decomposition extract is preferably administered so as to be 2000 mg / kg (body weight) or less per administration, more preferably 1500 mg / kg (body weight) or less, and further preferably 1000 mg / kg (body weight) or less. In addition, the saccharum officinarum bagasse decomposition extract is preferably administered so as to be 4000 mg / kg (body weight) or less per day, more preferably 3000 mg / kg (body weight) or less, and further preferably 2000 mg / kg (body weight) or less. If the range is within this range, a sufficient blood concentration can be achieved, and the anti-type I allergy effect can be more favorably exhibited.

[0230] In the case of oral administration of the anti-type I allergy agent, as the amount of administration, the decomposed extract of sugar cane bagasse is preferably administered at 50 μg / kg (body weight) or more per time, more preferably at 100 μg / kg (body weight) or more, and further preferably at 150 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered at 150 μg / kg (body weight) or more per day, more preferably at 300 μg / kg (body weight) or more, and further preferably at 450 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered at 1000 mg / kg (body weight) or less per time, more preferably at 800 mg / kg (body weight) or less, and further preferably at 600 mg / kg (body weight) or less. In addition, the decomposed extract of sugar cane bagasse is preferably administered at 3000 mg / kg (body weight) or less per day, more preferably at 2000 mg / kg (body weight) or less, and further preferably at 1000 mg / kg (body weight) or less. If it is within this range, a sufficient blood concentration can be achieved, and the anti-type I allergy effect can be more favorably exhibited.

[0231] The anti-type I allergy agent of the present embodiment has the above-mentioned effects, and thus can be used for patients with symptoms of type I allergy, and for allergy non-sufferers who wish to prevent type I allergy.

[0232] The specific mode of the degranulation inhibitor of mast cells or basophils of one embodiment can be the same as that of the anti-type I allergy agent described above. That is, the degranulation inhibitor of mast cells or basophils of one embodiment can be understood as "anti-type I allergy agent" in the description of the anti-type I allergy agent described above.

[0233] One embodiment of the present application can also be considered as an anti-type I allergy method or a method for inhibiting degranulation of mast cells or basophils, which includes the step of administering to a subject in need thereof an effective amount of an anti-type I allergy agent or a degranulation inhibitor of mast cells or basophils, containing the above-described decomposed extract of bagasse as an effective ingredient. In addition, one embodiment of the present application can be considered as a decomposed extract of bagasse for use in an anti-type I allergy method or a method for inhibiting degranulation of mast cells or basophils. The subject in the above-described method can be a mammal, preferably a human. The form of the anti-type I allergy agent or the degranulation inhibitor of mast cells or basophils, the method of administration, the amount of administration (intake amount), and the like are the same as described above.

[0234] Another embodiment of the present application can also be considered as use of a decomposed extract of bagasse for manufacturing an anti-type I allergy agent or a degranulation inhibitor of mast cells or basophils. In addition, one embodiment of the present application can also be considered as use of a decomposed extract of bagasse for an anti-type I allergy or for inhibiting degranulation of mast cells or basophils. The form of the anti-type I allergy agent or the degranulation inhibitor of mast cells or basophils is the same as described above.

[0235] <7th Embodiment: Anti-hypertensive Agent>

[0236] The anti-hypertensive agent of the present application has an anti-hypertensive effect. The anti-hypertensive effect can be an effect of inhibiting an increase in blood pressure.

[0237] Various mechanisms for regulating blood pressure exist in vivo. Angiotensin II has an effect of causing vasoconstriction, an effect of inhibiting excretion of sodium or water in the kidney to increase blood volume, and has an effect of increasing blood pressure. Angiotensin II is generated by conversion of angiotensin I by angiotensin converting enzyme (ACE). Therefore, by inhibiting ACE to inhibit generation of angiotensin II, it is possible to inhibit an increase in blood pressure.

[0238] The anti-hypertensive agent of the present application has an effect of inhibiting ACE, and therefore generation of angiotensin II is inhibited, and as a result, an increase in blood pressure can be inhibited. That is, the anti-hypertensive agent of the present application can be based on an inhibitory effect of angiotensin converting enzyme, and can also be based on an effect of inhibiting generation of angiotensin II. In addition, the present application can also provide an angiotensin converting enzyme inhibitor.

[0239] The anti-hypertensive agent of one embodiment contains the above-described decomposed extract of bagasse as an effective ingredient.

[0240] The antihypertensive agent can be used as a food composition, a medicine, or a quasi-drug. The food composition can be provided, for example, in the form of a health food, a specific health food, a functional food, a nutritionally functional food, a nutritional supplement, or the like.

[0241] The antihypertensive agent can be composed only of the decomposition extract of sugar cane bagasse as an effective ingredient, and can further be compounded with a material that can be used for a food composition, a quasi-drug, or a medicine. The material that can be used for a food composition, a quasi-drug, or a medicine is not particularly limited, and examples thereof include amino acids, proteins, carbohydrates, fats, sweeteners, minerals, vitamins, spices, excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, co-solvents, suspending agents, and the like. The proteins, carbohydrates, fats, sweeteners, minerals, vitamins, spices, excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, co-solvents, and suspending agents can be the same as those used in the obesity inhibitor described above.

[0242] In the case where the antihypertensive agent is compounded with other materials, the content of the decomposition extract of sugar cane bagasse as an effective ingredient can be appropriately set depending on the form of the antihypertensive agent, the purpose of use, and the like described below, and is preferably 1% by mass or more, more preferably 3% by mass or more, and further preferably 5% by mass or more, based on the solid content, from the viewpoint of more effectively exerting the antihypertensive effect, and is preferably 50% by mass or less, more preferably 40% by mass or less, and further preferably 30% by mass or less.

[0243] The antihypertensive agent is not limited in shape, and can be in any of a solid (powder, granules, and the like), a liquid (solution, suspension, and the like), a paste, and the like, and can be in any of a powder, a pill, granules, a tablet, a capsule, a lozenge, a liquid preparation, a suspension, and the like.

[0244] The antihypertensive agent can be administered orally, and can also be administered parenterally.

[0245] In the case of oral administration of an antihypertensive agent, as the amount of administration, for example, the decomposed extract of sugar cane bagasse is preferably administered so as to be 50 μg / kg (body weight) or more per time, more preferably 100 μg / kg (body weight) or more, and further preferably 150 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 150 μg / kg (body weight) or more per day, more preferably 300 μg / kg (body weight) or more, and further preferably 450 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 1000 mg / kg (body weight) or less per time, more preferably 800 mg / kg (body weight) or less, and further preferably 600 mg / kg (body weight) or less. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 3000 mg / kg (body weight) or less per day, more preferably 2000 mg / kg (body weight) or less, and further preferably 1000 mg / kg (body weight) or less. If it is within this range, a sufficient blood concentration can be achieved, and the antihypertensive effect can be more favorably exhibited.

[0246] In the case of non-oral administration of an antihypertensive agent, as the amount of administration, for example, the decomposed extract of sugar cane bagasse is preferably administered so as to be 100 μg / kg (body weight) or more per time, more preferably 150 μg / kg (body weight) or more, and further preferably 200 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 200 μg / kg (body weight) or more per day, more preferably 300 μg / kg (body weight) or more, and further preferably 400 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 2000 mg / kg (body weight) or less per time, more preferably 1500 mg / kg (body weight) or less, and further preferably 1000 mg / kg (body weight) or less. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 4000 mg / kg (body weight) or less per day, more preferably 3000 mg / kg (body weight) or less, and further preferably 2000 mg / kg (body weight) or less. If it is within this range, a sufficient blood concentration can be achieved, and the antihypertensive effect can be more favorably exhibited.

[0247] The antihypertensive agent can also be used as a feed, a feed additive. As the feed, there can be mentioned, for example, a feed for companion animals such as dog food, cat food, a feed for livestock, a feed for poultry, a feed for cultured seafood, and the like. The "feed" includes all foods that are taken orally by animals for nutritional purposes. More specifically, when classified from the viewpoint of the content of nutritional ingredients, it includes all of roughage, concentrated feed, inorganic feed, and special feed, and when classified from the viewpoint of official standards, it includes all of compounded feed, mixed feed, and single feed. Further, when classified from the viewpoint of the feeding method, it includes all of feed that is directly fed, feed that is mixed with other feed and fed, or feed that is added to drinking water for supplementing nutritional ingredients.

[0248] The specific mode of the angiotensin converting enzyme inhibitor of one embodiment can be the same as that of the above-described antihypertensive agent. That is, the angiotensin converting enzyme inhibitor of one embodiment can be understood as "antihypertensive agent" in the description of the above-described antihypertensive agent.

[0249] One embodiment of the present application can also be considered as an antihypertensive method or an angiotensin converting enzyme inhibition method, which includes a step of administering an effective amount of the above-described decomposition extract of bagasse as an effective component of an antihypertensive agent or an angiotensin converting enzyme inhibitor to a subject in need thereof. Further, one embodiment of the present application can be considered as the decomposition extract of bagasse for an antihypertensive method or an angiotensin converting enzyme inhibition method. The subject in the above-described method can be a mammal, preferably a human. The mode of the antihypertensive agent or the angiotensin converting enzyme inhibitor, the method of administration, the amount of administration (intake amount), and the like are the same as described above.

[0250] Another embodiment of the present application can also be considered as the use of the decomposition extract of bagasse for the production of an antihypertensive agent or an angiotensin converting enzyme inhibitor. Further, one embodiment of the present application can also be considered as the use of the decomposition extract of bagasse for antihypertension or for the inhibition of angiotensin converting enzyme. The mode of the antihypertensive agent or the angiotensin converting enzyme inhibitor is the same as described above.

[0251] <8th Embodiment: Flavor Improver>

[0252] The flavor improver of the present application has an effect of improving the flavor of a food or drink. The flavor includes all of the sensation felt when the taste and the smell exist each, or when the taste and the smell exist in combination, and the sensation felt when the taste and the stimulation to the throat exist in combination.

[0253] The satisfactory flavor is a flavor that is felt to be satisfactory by a person, and for example, there can be mentioned deliciousness, refreshingness, lightness, ease of eating, ease of drinking, richness, palatability, the flavor of the material as it is, and the like.

[0254] Unpleasant taste is a flavor that a person feels unpleasant, and examples thereof include sour taste, bitter taste, foul smell, egg smell, miscellaneous smell, unpleasant aftertaste, rancid smell, steamed sterilization smell, dry smell, oil smell, egg smell, meat fishy smell, fish fishy smell, green smell of beans and vegetables, greasy feeling, stimulating feeling, powder feeling, sticky feeling of taste, metallic taste, and the like.

[0255] In one embodiment, the flavor improver of the present application has an effect of enhancing a pleasant flavor of a food or drink. The effect of enhancing a pleasant flavor of a food or drink can be an effect of more strongly feeling the above-mentioned pleasant flavor. That is, the flavor improver of one embodiment can be based on the effect of enhancing a pleasant flavor of a food or drink. In addition, the present application can also provide a pleasant flavor enhancer of a food or drink.

[0256] In other embodiments, the flavor improver of the present application has an effect of reducing an unpleasant taste of a food or drink. The effect of reducing an unpleasant taste of a food or drink can be an effect of more hardly feeling the above-mentioned unpleasant taste of a food or drink. That is, the flavor improver of one embodiment can be based on the effect of reducing an unpleasant taste of a food or drink. In addition, the present application can also provide an unpleasant taste reducer of a food or drink.

[0257] The flavor improver can have either of the effects of enhancing a pleasant flavor of a food or drink and reducing an unpleasant taste, and can also have both of the effects.

[0258] The flavor improver of one embodiment contains the above-mentioned decomposed extract of sugar cane bagasse.

[0259] The flavor improver can be composed only of the decomposed extract of sugar cane bagasse, and can further be compounded with a material that can be used for a food composition (food or drink). As the material that can be used for a food composition, there is no particular limitation, and examples thereof include amino acids, proteins, carbohydrates, fats and oils, sweeteners, minerals, vitamins, spices, excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, co-solvents, suspending agents, and the like. As the proteins, carbohydrates, fats and oils, sweeteners, minerals, vitamins, spices, excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, co-solvents, and suspending agents, the same materials as those used in the above-mentioned obesity inhibitor can be used.

[0260] In the case where other materials are compounded in the flavor improver, the content of the decomposition extract of sugar cane bagasse is appropriately set according to the purpose of use of the flavor improver or the like, and from the viewpoint of more effectively exerting the flavor improving effect, it is preferably 0.1% by mass or more, more preferably 0.3% by mass or more, further preferably 0.5% by mass or more, and on the other hand, it is preferably 90% by mass or less, more preferably 80% by mass or less, further preferably 70% by mass or less, based on the solid content.

[0261] By adding the above-described flavor improver to various food and drink products, it is possible to improve the flavor of the food and drink products. More specifically, by adding the flavor improver to the food and drink products, it is possible to enhance the satisfactory flavor of the food and drink products and / or reduce the unpleasant taste of the food and drink products. Adding the flavor improver to the food and drink products includes attaching or impregnating the flavor improver to the food and drink products. As a result, the food and drink products contain the flavor improver. That is, the food and drink products of one embodiment include the flavor improver containing the decomposition extract of sugar cane bagasse, and are food and drink products whose flavor is improved. The food and drink products containing the flavor improver include food and drink products to which the flavor improver is attached and food and drink products to which the flavor improver is impregnated.

[0262] In addition to the usual food and drink products, the food and drink products include health foods, specified health foods, functional foods, nutritionally functional foods, nutritional supplements, and the like. The food and drink products can be beverages such as milk beverages, lactic acid bacteria beverages, soy milk beverages, vegetable beverages, fruit beverages, teas, coffee beverages, alcoholic beverages, other refreshing beverage waters (beverages containing vinegar and the like), and the like; foods such as noodles, breads, vegetable processed products, fruit processed products, meat products, processed seafood, dairy products, soy products, soups, seasonings, and the like. The food and drink products whose flavor is improved by the flavor improver are preferably soy milk beverages, beverages containing vinegar, lactic acid bacteria beverages, meat products, or processed seafood.

[0263] For example, in the case where the food and drink products are soy milk beverages, the flavor improver can enhance the satisfactory flavor of the soy milk beverages. The satisfactory flavor of the soy milk beverages can be refreshing, deliciousness, lightness, ease of drinking, and the like. The flavor improver can reduce the unpleasant taste of the soy milk beverages. The unpleasant taste of the soy milk beverages can be the greenish smell of soybeans, an unpleasant aftertaste, an egg smell, an off-flavor, and the like.

[0264] In the case where the food and drink products are beverages containing vinegar (vinegar-containing beverages), the flavor improver can enhance the satisfactory flavor of the vinegar-containing beverages. The satisfactory flavor of the vinegar-containing beverages can be ease of drinking, deliciousness, lightness, richness, mouthfeel, and the like. The flavor improver can reduce the unpleasant taste of the vinegar-containing beverages. The unpleasant taste of the vinegar-containing beverages can be sourness, an unpleasant aftertaste, and the like.

[0265] When the food or drink is a lactic acid bacteria beverage, the flavor improver can enhance the satisfactory flavor of the lactic acid bacteria beverage. The satisfactory flavor of the lactic acid bacteria beverage can be lightness, refreshing, ease of drinking, deliciousness, strong aftertaste, and the like. The flavor improver can reduce the unpleasant taste of the lactic acid bacteria beverage. The unpleasant taste of the lactic acid bacteria beverage can be off-flavor, and the like.

[0266] When the food or drink is a meat product, the flavor improver can enhance the satisfactory flavor of the meat product. The satisfactory flavor of the meat product can be the flavor of meat as it is, deliciousness, ease of eating, lightness, and the like. The flavor improver can reduce the unpleasant taste of the meat product. The unpleasant taste of the meat product can be unpleasant aftertaste, the smell of meat, greasiness, and the like.

[0267] When the food or drink is a processed seafood, the flavor improver can enhance the satisfactory flavor of the processed seafood. The satisfactory flavor of the processed seafood can be the flavor of seafood as it is, deliciousness, ease of eating, lightness, and the like. The flavor improver can reduce the unpleasant taste of the processed seafood. The unpleasant taste of the processed seafood can be unpleasant aftertaste, the smell of seafood, greasiness, and the like.

[0268] The amount of the flavor improver added to the food or drink can be appropriately selected depending on the kind of the food or drink to be added. The amount of the decomposition extract of sugar cane bagasse contained in the flavor improver can be 0.3 mass ppm or more, 0.6 mass ppm or more, 0.8 mass ppm or more, 3 mass ppm or more, 5 mass ppm or more, or 10 mass ppm or more, and can be 50 mass ppm or less, 40 mass ppm or less, or 30 mass ppm or less, based on the total amount of the food or drink. If the amount of the flavor improver is in this range, sufficient flavor improvement effect can be obtained.

[0269] The specific mode of the satisfactory flavor enhancer for food or drink and the unpleasant taste reducer for food or drink of one embodiment can be the same as that of the flavor improver described above. That is, the satisfactory flavor enhancer for food or drink and the unpleasant taste reducer for food or drink of one embodiment can be understood as the "flavor improver" in the description of the flavor improver described above.

[0270] One embodiment of the present application can also be considered as a flavor improving method, a method for enhancing a pleasant flavor of a food or drink, or a method for reducing an unpleasant taste of a food or drink, which includes the step of adding to a subject in need thereof an effective amount of a flavor improver, a pleasant flavor enhancer of a food or drink, or an unpleasant taste reducer of a food or drink, which contains the above-described decomposed extract of sugar cane residue as an effective ingredient. In addition, one embodiment of the present application can be considered as a decomposed extract of sugar cane residue for use in a flavor improving method, a method for enhancing a pleasant flavor of a food or drink, or a method for reducing an unpleasant taste of a food or drink. The subject in the above-described method can be a food or drink. The form, administration method, administration amount (ingestion amount), and the like of the flavor improver, the pleasant flavor enhancer of a food or drink, or the unpleasant taste reducer of a food or drink are the same as described above.

[0271] Another embodiment of the present application can also be considered as an application of a decomposed extract of sugar cane residue for manufacturing a flavor improver, a pleasant flavor enhancer of a food or drink, or an unpleasant taste reducer of a food or drink. In addition, one embodiment of the present application can also be considered as an application of a decomposed extract of sugar cane residue for improving the flavor of a food or drink, for enhancing a pleasant flavor of a food or drink, or for reducing an unpleasant taste of a food or drink. The form of the flavor improver, the pleasant flavor enhancer of a food or drink, or the unpleasant taste reducer of a food or drink is the same as described above.

[0272] <9th Embodiment: Muscle Strengthening Agent>

[0273] The muscle strengthening agent of the present application has a muscle strengthening effect. The muscle strengthening effect in the present specification includes a myotube cell differentiation promoting effect of promoting differentiation of myoblast cells into myotube cells and a mitochondrion activating effect of activating mitochondria in muscle. That is, the present application can provide a myotube cell differentiation promoter or a mitochondrion activator.

[0274] The mitochondrion activating effect includes an effect of increasing the amount of mitochondria present in cells (muscle cells) in muscle (mitochondrion amount per cell) and further an effect of increasing the activity of mitochondria present in muscle cells (mitochondrion activity per cell). That is, the present application can also provide a mitochondrion augmenting agent in muscle cells or a mitochondrion activator in muscle cells.

[0275] The muscle strengthening agent of one embodiment contains the above-described decomposed extract of sugar cane residue as an effective ingredient.

[0276] The muscle strengthening agent can be used as a food composition, a drug, or a quasi-drug. The food composition can be provided, for example, in the form of a health food, a specific health food, a functional food, a nutritionally functional food, a nutrition enhancer, or the like. That is, according to the present application, a food composition for muscle strengthening, a drug for muscle strengthening, or a quasi-drug for muscle strengthening can also be provided.

[0277] The muscle enhancer can be composed of only the decomposition extract of sugar cane bagasse as an effective ingredient, and can further contain a material usable for a food composition, quasi-drug, or drug. The material usable for a food composition, quasi-drug, or drug is not particularly limited, and for example, amino acids, proteins, carbohydrates, fats, sweeteners, minerals, vitamins, spices, excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, co-solvents, suspending agents, and the like can be exemplified. As the proteins, carbohydrates, fats, sweeteners, minerals, vitamins, spices, excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, co-solvents, and suspending agents, the same materials as those used in the obesity inhibitor described above can be used.

[0278] In the case where other materials are compounded in the muscle enhancer, the content of the decomposition extract of sugar cane bagasse as an effective ingredient can be appropriately set according to the form of the muscle enhancer, purpose of use, and the like described later, and from the viewpoint of more effectively exerting the muscle enhancing effect, it is preferred to be 0.5% by mass or more, more preferably 1% by mass or more, and further preferably 3% by mass or more, in terms of solid content, and it is preferred to be 50% by mass or less, more preferably 40% by mass or less, and further preferably 30% by mass or less.

[0279] The muscle enhancer is not limited in shape, and can be in any of a solid (powder, granules, and the like), a liquid (solution, suspension, and the like), a paste, and the like, and can be in any of a powder, a pill, granules, a tablet, a capsule, a lozenge, a liquid preparation, a suspension, and the like.

[0280] The muscle enhancer can be administered orally, and can also be administered parenterally such as intravenously.

[0281] In the case of oral administration of the muscle enhancer, as the administration amount, for example, the decomposed extract of sugar cane bagasse is preferably administered so as to be 50 μg / kg (body weight) or more per time, more preferably 100 μg / kg (body weight) or more, and further preferably 150 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 150 μg / kg (body weight) or more per day, more preferably 300 μg / kg (body weight) or more, and further preferably 450 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 1000 mg / kg (body weight) or less per time, more preferably 800 mg / kg (body weight) or less, and further preferably 600 mg / kg (body weight) or less. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 3000 mg / kg (body weight) or less per day, more preferably 2000 mg / kg (body weight) or less, and further preferably 1000 mg / kg (body weight) or less. If it is within this range, a sufficient blood concentration can be achieved, and the muscle enhancing effect can be more effectively exhibited.

[0282] In the case of non-oral administration of the muscle enhancer, as the administration amount, for example, the decomposed extract of sugar cane bagasse is preferably administered so as to be 50 μg / kg (body weight) or more per time, more preferably 150 μg / kg (body weight) or more, and further preferably 250 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 100 μg / kg (body weight) or more per day, more preferably 300 μg / kg (body weight) or more, and further preferably 500 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 2000 mg / kg (body weight) or less per time, more preferably 1500 mg / kg (body weight) or less, and further preferably 1000 mg / kg (body weight) or less. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 4000 mg / kg (body weight) or less per day, more preferably 3000 mg / kg (body weight) or less, and further preferably 2000 mg / kg (body weight) or less. If it is within this range, a sufficient blood concentration can be achieved, and the muscle enhancing effect can be more effectively exhibited.

[0283] The muscle enhancer of the present embodiment can be used for humans or animals. When the muscle enhancer is used for animals, it can be used as a feed, a feed additive. As the feed, there can be mentioned a companion animal feed such as dog food, cat food, a livestock feed, a poultry feed, a feed for cultured seafood, and the like. The "feed" includes all foods that are taken orally by animals for nutritional purposes. More specifically, when classified from the viewpoint of the content of nutritional ingredients, it includes all of roughage, concentrated feed, inorganic feed, and special feed, and when classified from the viewpoint of official standards, it includes all of compounded feed, mixed feed, and single feed. Further, when classified from the viewpoint of the feeding method, it includes all of feed that is directly fed, feed that is mixed with other feed and fed, or feed that is added to drinking water for supplementing nutritional ingredients.

[0284] The muscle enhancer of the present embodiment can be used for promoting the formation of muscle, for promoting the recovery of injured muscle, or for activating the function of formed muscle.

[0285] The specific mode of the mitochondrial activator or the myoblast cell differentiation promoter of one embodiment can be the same as that of the muscle enhancer described above. That is, the mitochondrial activator or the myoblast cell differentiation promoter of one embodiment can be understood as "muscle enhancer" in the description of the muscle enhancer described above.

[0286] One embodiment of the present application can also be considered as a muscle enhancement method, a mitochondrial activation method, or a myoblast cell differentiation promotion method, which includes a step of administering to a subject in need thereof an effective amount of a muscle enhancer, a mitochondrial activator, or a myoblast cell differentiation promoter containing the decomposition extract of sugar cane bagasse as an effective ingredient. Further, one embodiment of the present application can be considered as a decomposition extract of sugar cane bagasse for use in a muscle enhancement method, a mitochondrial activation method, or a myoblast cell differentiation promotion method. The subject in the above method can be a mammal, preferably a human. The mode of the muscle enhancer, the mitochondrial activator, or the myoblast cell differentiation promoter, the method of administration, the amount of administration (intake amount), and the like are the same as described above.

[0287] Another embodiment of the present application can also be considered as the use of a decomposition extract of sugar cane bagasse for the production of a muscle enhancer, a mitochondrial activator, or a myoblast cell differentiation promoter. Further, one embodiment of the present application can also be considered as the use of a decomposition extract of sugar cane bagasse for enhancing muscle, for activating mitochondria, or for promoting differentiation into myoblast cells. The mode of the muscle enhancer, the mitochondrial activator, or the myoblast cell differentiation promoter is the same as described above.

[0288] <10th Embodiment: Bone Metabolism Improver>

[0289] The bone metabolism improver of the present application has an improving effect on bone metabolism. The improving effect on bone metabolism can be at least one of an effect of promoting bone formation (formation of new bone) and an effect of inhibiting excessive bone resorption (breakage of bone). Thus, the balance between bone formation and bone resorption can be appropriately adjusted, and as a result, the reconstruction of bone can be easily performed. That is, the present application can provide a bone formation promoter and a bone resorption inhibitor, and can also provide a balance adjustor of bone formation and bone resorption.

[0290] The promotion of bone formation in the bone formation promoter can be based on an effect of promoting the differentiation of osteoblasts. That is, the bone formation promoter in the present specification can also be referred to as an osteoblast differentiation promoter. In addition, the inhibition of bone resorption in the bone resorption inhibitor can be based on an effect of inhibiting the differentiation of osteoclasts. That is, the bone resorption inhibitor in the present specification can also be referred to as an osteoclast differentiation inhibitor.

[0291] The bone formation promoter of one embodiment contains the decomposition extract of sugar cane bagasse described above as an effective component.

[0292] The bone metabolism improver can be used as a food composition, a drug, or a quasi-drug. The food composition can be provided, for example, in the form of a health food, a specific health food, a functional food, a nutritionally functional food, a nutritional supplement, or the like. That is, according to the present application, a food composition for improving bone metabolism, a drug for improving bone metabolism, or a quasi-drug for improving bone metabolism can also be provided.

[0293] The bone metabolism improver can be composed only of the decomposition extract of sugar cane bagasse as an effective component, and can further contain a material that can be used for a food composition, a quasi-drug, or a drug. The material that can be used for a food composition, a quasi-drug, or a drug is not particularly limited, and for example, amino acids, proteins, carbohydrates, fats, sweeteners, minerals, vitamins, spices, excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, co-solvents, suspending agents, and the like can be exemplified. As the proteins, carbohydrates, fats, sweeteners, minerals, vitamins, spices, excipients, binders, lubricants, disintegrants, emulsifiers, surfactants, bases, co-solvents, and suspending agents, the same materials as those used in the obesity inhibitor described above can be used.

[0294] The shape of the bone metabolism improver is not limited, and can be any of a solid (powder, granules, and the like), a liquid (solution, suspension, and the like), a paste, and the like, and can be any of a dosage form of a powder, a pill, granules, a tablet, a capsule, a lozenge, a liquid preparation, a suspension, and the like.

[0295] The bone metabolism improver can be administered orally, and can also be administered parenterally.

[0296] In the case of oral administration of the bone metabolism improver, as the amount of administration, for example, the decomposed extract of sugar cane bagasse is preferably administered so as to be 50 μg / kg (body weight) or more per time, more preferably 100 μg / kg (body weight) or more, and further preferably 150 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 150 μg / kg (body weight) or more per day, more preferably 300 μg / kg (body weight) or more, and further preferably 450 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 1000 mg / kg (body weight) or less per time, more preferably 800 mg / kg (body weight) or less, and further preferably 600 mg / kg (body weight) or less. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 3000 mg / kg (body weight) or less per day, more preferably 2000 mg / kg (body weight) or less, and further preferably 1000 mg / kg (body weight) or less. If it is within this range, a sufficient blood concentration can be achieved, and the bone metabolism improving effect can be more effectively exhibited.

[0297] In the case of non-oral administration of the bone metabolism improver, as the amount of administration, for example, the decomposed extract of sugar cane bagasse is preferably administered so as to be 50 μg / kg (body weight) or more per time, more preferably 150 μg / kg (body weight) or more, and further preferably 250 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 100 μg / kg (body weight) or more per day, more preferably 300 μg / kg (body weight) or more, and further preferably 500 μg / kg (body weight) or more. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 2000 mg / kg (body weight) or less per time, more preferably 1500 mg / kg (body weight) or less, and further preferably 1000 mg / kg (body weight) or less. In addition, the decomposed extract of sugar cane bagasse is preferably administered so as to be 4000 mg / kg (body weight) or less per day, more preferably 3000 mg / kg (body weight) or less, and further preferably 2000 mg / kg (body weight) or less. If it is within this range, a sufficient blood concentration can be achieved, and the bone metabolism improving effect can be more effectively exhibited.

[0298] The bone metabolism improver of the present embodiment can be used for humans or animals. When the bone metabolism improver is used for animals, it can be used as a feed, a feed additive. As the feed, there can be listed companion animal feeds such as dog food, cat food, livestock feeds, poultry feeds, and aquaculture feeds. The "feed" includes all foods that are taken orally by animals for nutritional purposes. More specifically, when classified from the viewpoint of the content of nutritional ingredients, it includes all of roughage, concentrated feed, inorganic feed, and special feed, and when classified from the viewpoint of official standards, it includes all of compounded feed, mixed feed, and single feed. Further, when classified from the viewpoint of the feeding method, it includes all of feed that is directly fed, feed that is mixed with other feed and fed, or feed that is added to drinking water for supplementing nutritional ingredients.

[0299] The bone metabolism improver described above can improve bone metabolism in humans or animals other than humans, and thus can also be used for preventive and therapeutic purposes for bone-related diseases such as bone fracture, osteoporosis, and osteomalacia.

[0300] The specific mode of the bone formation promoter and the bone resorption inhibitor of one embodiment can be the same as that of the bone metabolism improver described above. That is, the bone formation promoter or the bone resorption inhibitor of one embodiment can be understood as "bone metabolism improver" in the description of the bone metabolism improver described above.

[0301] One embodiment of the present application can also be considered as a bone metabolism improvement method, a bone formation promotion method, or a bone resorption inhibition method, which includes a step of administering to a subject in need thereof an effective amount of a bone metabolism improver, a bone formation promoter, or a bone resorption inhibitor containing the decomposition extract of sugar cane bagasse described above as an effective ingredient. Further, one embodiment of the present application can be considered as a decomposition extract of sugar cane bagasse for use in a bone metabolism improvement method, a bone formation promotion method, or a bone resorption inhibition method. The subject in the method described above can be a mammal, preferably a human. The mode of the bone metabolism improver, the bone formation promoter, or the bone resorption inhibitor, the method of administration, the amount of administration (intake amount), and the like are the same as described above.

[0302] Another embodiment of the present application can also be considered as an application of a decomposition extract of sugar cane bagasse for manufacturing a bone metabolism improver, a bone formation promoter, or a bone resorption inhibitor. Further, one embodiment of the present application can also be considered as an application of a decomposition extract of sugar cane bagasse for improving bone metabolism, for promoting bone formation, or for inhibiting bone resorption. The mode of the bone metabolism improver, the bone formation promoter, or the bone resorption inhibitor is the same as described above.

[0303] Example

[0304] The present application will be described below by way of examples, but the present application is not limited to these examples. Note that the decomposed extract of sugarcane bagasse is sometimes simply referred to as "extract" hereinafter.

[0305] <Manufacture of the decomposed extract of sugarcane bagasse>

[0306] [Manufacturing Example 1]

[0307] Sugarcane bagasse 15 kg (water content 50 mass%) as a pressed residue of sugarcane and 0.5% (w / w) sodium hydroxide aqueous solution 100 L were mixed, and alkali treatment was performed at 150°C. The mixed solution after the alkali treatment was separated into solid components and liquid components, and about 100 L of the liquid components were obtained. Ultrafiltration was performed using a UF membrane (SUEZ Corporation, GH8040F30) with a molecular weight cut-off of 2500, and 80 L of a filtrate was obtained. Synthetic adsorbent (Mitsubishi Chemical Corporation, HP-20) 1 L was packed in a resin column (inner diameter 80 mm, height 400 mm), and the pH of the above-mentioned filtrate was adjusted to 6, and then passed therethrough at a flow rate of 10 L / hour (SV = 10.0 (hour -1 ))

[0308] Next, 5 L of purified water was passed through the resin column at a flow rate of 10 L / hour (SV = 10.0 (hour -1 ) ). Next, 2 L of 60% ethanol aqueous solution (ethanol / water = 60 / 40 (volume / volume)) as an elution solvent was passed through the resin column at a flow rate of 2 L / hour (SV = 2.0 (hour -1 ) ). Next, 2 L of purified water was passed through the resin column at a flow rate of 2 L / hour (SV = 2.0 (hour -1 ) ), and the components adsorbed to the synthetic adsorbent were eluted. The fraction eluted from the resin column was concentrated to about 10 times the concentration by a rotary evaporator under reduced pressure, and then freeze-dried overnight, and a tea-brown powder 20 g was obtained as the decomposed extract of sugarcane bagasse. This was used as Extract A.

[0309] [Manufacturing Example 2]

[0310] Sugarcane bagasse 30 kg (water content 50 mass%) as a pressed residue of sugarcane was subjected to hydrothermal treatment at 200°C under 1.8 MPa in hot water 100 L. The mixture after the pretreatment was separated into a solid component and a liquid component, and the liquid component was obtained as about 88 L. The liquid component was subjected to ultrafiltration using a UF membrane (SUEZ Corporation, GH8040F30) with a molecular weight cut-off of 2500, and a filtrate 70 L was obtained. 1 L of a synthetic adsorbent (SP-850 manufactured by Mitsubishi Chemical Corporation) was packed in a resin column (inner diameter 80 mm, height 400 mm), and 25 L of the filtrate was passed through the resin column at a flow rate of 20 L / hour (SV = 20.0 (hour -1 )).

[0311] Next, 3.3 L of purified water was passed through the resin column at a flow rate of 20 L / hour (SV = 20.0 (hour -1 )) for washing. Next, 2 L of 60% ethanol aqueous solution (ethanol / water = 60 / 40 (volume / volume)) as an elution solvent was passed through the resin column at a flow rate of 2 L / hour (SV = 2.0 (hour -1 )). Next, 2 L of purified water was passed through the resin column at a flow rate of 2 L / hour (SV = 2.0 (hour -1 )) to elute the components adsorbed to the synthetic adsorbent. The fraction eluted from the resin column was concentrated to about 10 times the concentration by a rotary evaporator under reduced pressure, and then lyophilized overnight to obtain a brownish yellow powder 40 g as a decomposed extract of sugarcane bagasse. This was used as the extract W.

[0312] [Experiment a: Test as an obesity inhibitor]

[0313] [Experiment a1: Test as an obesity inhibitor based on the extract A]

[0314] [Preparation of a test solution]

[0315] The extract A was dissolved in water to obtain a test solution stock solution at 50 mg / mL. The test solution stock solution was diluted with DMEM medium to prepare a test solution at a test substance concentration of 2000 μg / mL.

[0316] [3T3-L1 cell fat accumulation inhibition test]

[0317] (Culture of cells)

[0318] 3T3-L1 cells (National Institute of Biomedical Innovation, Health and Nutrition) as mouse adipocyte precursor cells were inoculated in a 24-well plate and cultured for 4 days with DMEM medium containing newborn calf serum (10 vol%, based on the total amount of the medium) and a penicillin-streptomycin solution (1 vol%, based on the total amount of the medium). After the culture, the medium was replaced with DMEM medium containing fetal bovine serum (10 vol%, based on the total amount of the medium) and a penicillin-streptomycin solution (1 vol%, based on the total amount of the medium), and the 3T3-L1 cells were differentiated into adipocytes using an adipogenesis assay kit (Cayman Chemical Co.). At this time, the prepared test solution of 2000 μg / mL was added at a final concentration of 1000 μg / mL (Example a1). After 3 days of culture, the medium was replaced with a freshly prepared test solution. In addition, cells that were not subjected to differentiation induction based on the adipogenesis assay kit were used as precursor cells (undifferentiated a1-1), cells to which no test solution was added were used as an untreated control (Comparative Example a1-1), and cells to which berberine hydrochloride (Wako Pure Chemical Industries, Ltd.) was added at a final concentration of 1 μg / mL were used as a positive control (Positive Control a1-1), and the same test was performed. These were further cultured for 4 days.

[0319] (Staining of cells)

[0320] After the culture, the culture supernatant was removed, and the cells were fixed according to the steps of the adipogenesis assay kit, and then the cells were stained with an oil red O solution as a lipophilic dye for staining fat droplets.

[0321] [Observation of fat droplets]

[0322] Using an inverted phase-contrast microscope, the results of staining of fat droplets accumulated in the adipocytes were observed. The observation results of each sample are shown in Figure 1 . Figure 1 (a) is the precursor cells (undifferentiated a1-1), (b) is Comparative Example a1-1, (c) is Positive Control a1-1, and (d) is Example a1. As a result, in the adipocytes of Comparative Example a1-1, accumulation of fat droplets stained with oil red O could be observed, but in the adipocytes of Example a1, the accumulated fat droplets were less than in the adipocytes of Comparative Example a1-1.

[0323] [Measurement of fat accumulation rate]

[0324] After observing the fat droplets, the pigment extract solution contained in the fat production assay kit was added to the samples of Example al, Comparative Example al-1 and Positive Control al-1, and oil red O incorporated in the fat droplets was extracted. The absorbance of the extracted oil red O was measured at 520 nm using a microplate reader (SpectraMax M2e, Molecular Devices Corporation).

[0325] Based on the absorbance of each sample, the fat accumulation rate was calculated using the following equation.

[0326] Fat accumulation rate (%) = {(Sa - BL Avr ) / (CN - BL Avr ) Avr} x 100

[0327] Sa: absorbance of each sample

[0328] BL Avr : average value of absorbance of precursor cells (undifferentiated al-1) (n = 3)

[0329] CN: absorbance of Comparative Example al-1 (untreated control)

[0330] (CN - BL Avr ) Avr : average value of the value obtained by subtracting BL Avr from CN (n = 3)

[0331] The results of the calculation of the fat accumulation rate are shown in Figure 2 . For the fat accumulation rate, Comparative Example al-1 was 100 ± 5.5%, while Positive Control al-1 was 19 ± 1.0, and Example al was 15 ± 1.5.

[0332] [Experiment Example a2: Obesity Inhibition Test Based on Extract W]

[0333] [Preparation of Test Solution]

[0334] Extract W was dissolved in ethanol to obtain a test solution stock solution at 50 mg / mL. The test solution stock solution was diluted with DMEM medium to prepare a test solution at a test substance concentration of 500 μg / mL.

[0335] [3T3-L1 Cell Fat Accumulation Inhibition Test]

[0336] The fat accumulation inhibition test was performed using the same method as in Test Example a1, except that the test solution containing the prepared extract W was added to a final concentration of 250 μg / mL (Example a2). Similarly to Test Example a1, the test was performed using cells that had not undergone differentiation induction using the adipogenesis analysis kit as precursor cells (undifferentiated a1-2) and cells to which the test solution was not added as an untreated control (Comparative Example a1-2).

[0337] [Observation of fat droplets]

[0338] The results of staining of fat droplets accumulated in adipocytes were observed using the same method as in Test Example a1. The observation results of each sample are shown in FIG. Figure 3 . Figure 3 In the figure, (a) shows the results of observation of precursor cells (undifferentiated a1-2), (b) shows the results of observation of Comparative Example a1-2, and (c) shows the results of observation of Example a2. The results show that accumulation of fat droplets stained with Oil Red O was observed in the adipocytes of Comparative Example a1-2, but the accumulation of fat droplets in the adipocytes of Example a2 was less than that in the adipocytes of Comparative Example a1-2.

[0339] [Determination of fat accumulation rate]

[0340] After observing the fat droplets, the fat accumulation rate was calculated for Example a2 and Comparative Example a1-2 using the same method as in Test Example a1. The results are shown in Figure 4 The fat accumulation rate was 100±5.6% in Comparative Example a1-2, and 20±5.6% in Example a2.

[0341] <Test b: Test as an anti-dementia agent>

[0342] [Preparation of test solution]

[0343] Extracts A and W were stored in powder form at room temperature (management temperature: 18.0-28.0°C) prior to testing. Water for injection (Otsuka distilled water, Otsuka Pharmaceutical Co., Ltd.) was prepared as a medium for dissolving the extracts. The required amount of extract was weighed, dissolved in water for injection, and diluted to the specified concentration to prepare the test solution.

[0344] [Preparation of β-amyloid solution]

[0345] As the amyloid-β protein (25-35) (Polypeptide Laboratories, Inc.) used in the amyloid-β solution, the amyloid-β was frozen (management temperature: -30 to -20°C (actual measurement: -27.1 to -24.0°C)) until use in the test. The amyloid-β was dissolved in water for injection to make 2 mM, and an amyloid-β solution was prepared.

[0346] [Test animals]

[0347] As the test animals, male Slc:ddY mice (SPF, manufactured by Japan SLC, Inc.) were used. As the mice, 5-week-old mice were obtained. The mice are a kind of animals commonly used in behavioral pharmacological tests, and the lineage is well maintained. The body weight of the mice obtained one day after the acquisition ranged from 23.8 to 30.0 g. The obtained mice were subjected to a pre-feeding period of 5 days.

[0348] (Feeding conditions)

[0349] The mice were fed in an animal feeding room maintained at a management temperature of 20.0 to 26.0°C, a management humidity of 40.0 to 70.0%, 12 hours of light and dark each (lighting: 6 a.m. to 6 p.m.), and an air exchange number of 12 times / hour (fresh air through a filter).

[0350] From the pre-feeding period to the grouping day, plastic cages (W: 310 x D: 360 x H: 175 mm) were used, and a maximum of 10 mice were fed per cage, and a maximum of 5 mice were fed per cage after grouping. As the feed, solid feed (MF, manufactured by Oriental Yeast Co., Ltd.) and tap water were allowed to be freely taken as beverage water, respectively.

[0351] (Grouping method and solid recognition method)

[0352] Grouping was performed on the day of the start of administration of the test solution using a random sampling method so that the average body weight of each group was almost uniform. As the group composition, four groups of a sham operation group, a medium control group, an extract A administration group, and an extract W administration group were set. In the extract A administration group, as the amount of the administration solution, the administration amount of extract A was calculated to be 10 mL / kg based on the body weight on the administration day in such a manner that the administration amount of extract A per mouse became 500 mg / kg. Similarly, in the extract W administration group, as the amount of the administration solution, the administration amount of extract W was calculated to be 10 mL / kg based on the body weight on the administration day in such a manner that the administration amount of extract W per mouse became 500 mg / kg. In the sham operation group and the medium control group, 0.5% (w / v) methylcellulose solution was administered at 10 mL / kg.

[0353] (Schedule of the experiment)

[0354] The start day of the administration of the test solution was taken as the first day of administration, and the test solution was administered once a day. On the eighth day of administration, the amyloid beta solution was injected into the mice. Then, the Y-maze test was performed on the fourteenth day of administration. Each step is described below.

[0355] (Administration route and administration method of the test solution)

[0356] The administration route was oral administration. As the administration method, the test solution was administered orally using a polypropylene disposable syringe (TERUMO CORPORATION) equipped with a disposable oral probe for mice (Fuchigami Instrument) in accordance with the usual method used in the test facility. At the time of administration, the test solution was mixed by inverting and drawing into the syringe every time 1 administration was performed. Note that, on the day of injection of the amyloid beta solution, the test solution was administered after the injection of the amyloid beta solution, and on the day of the Y-maze test, the test solution was administered 30 minutes before measurement.

[0357] (Injection method of amyloid beta

[0358] The mice were anesthetized by intraperitoneal administration (dose: 10 mL / kg) of sodium pentobarbital (Tokyo Chemical Industry Co., Ltd.) at 40 mg / kg. After anesthesia, levobupivacaine hydrochloride (Bobskine (registered trademark) 0.25% injection, Maruishi Pharmaceutical Co., Ltd.) was administered subcutaneously (0.1 mL) to the scalp. The scalp was incised to expose the skull, and a hole for insertion of a stainless steel tube for a silicone tube was made in the skull 1 mm laterally (right side) and 0.2 mm posteriorly from the bregma using a dental drill. A stainless steel tube connected to a silicone tube with an outer diameter of 0.5 mm and a microsyringe were vertically inserted to a depth of 2.5 mm from the bone surface. In the SCE1 administration group and the vehicle control group, 3 μL (6 nmol / 3 μL) of the amyloid beta solution was injected into the brain ventricle using a microsyringe pump for 3 minutes. On the other hand, in the sham operation group, 3 μL of water for injection was injected in the same manner. After injection, the stainless steel tube was left inserted for 3 minutes, and then removed slowly. Then, the skull hole was plugged with a non-absorbable bone marrow hemostatic agent (NESTP (registered trademark), Alfresa Pharma Corporation), and the scalp was sutured.

[0359] (Evaluation based on the Y-maze test)

[0360] The Y-maze test, which is known as a method for evaluating learning and memory behavior, particularly a method for evaluating short-term memory, was performed (for example, Non-Patent Literature 1). In the test, a plastic Y-maze (manufactured by Unicom) having 3 arms each bifurcated at 120 degrees, with an arm length of 39.5 cm, a floor width of 4.5 cm, and a wall height of 12 cm was used.

[0361] Before the evaluation, the illuminance of the floor of the apparatus was adjusted to 10 to 40 lux. The evaluation was performed 30 minutes after administration of the test solution. The mouse was placed in any of the arms of the Y-maze, and allowed to freely explore in the maze for 8 minutes. The order of the arms in which the mouse moved was recorded, and the number of times of moving in the arms was counted as the total number of entries. Next, the combination in which 3 different arms were continuously selected was investigated, and the number was taken as the number of autonomous alternation behavior. In addition, the autonomous alternation behavior rate was calculated using the following equation.

[0362] Autonomous alternation behavior rate (%) = [number of autonomous alternation behavior / (total number of entries - 2)] x 100

[0363] The Y-maze test was performed on the mice of each group, and the mean and standard error of the total number of entries, the number of autonomous alternation behavior, and the autonomous alternation behavior rate were calculated. Note that, for the test of significant difference, the medium control group and the extract administration group were directly compared with the sham operation group. The test of variance homogeneity based on F test was performed between the two groups, Student's t test was performed in the case of homoscedasticity, and Aspin-Welch test was performed in the case of heteroscedasticity. The significance was 1%. The test of significant difference used a commercially available statistical program (SAS system, SAS Institute Japan). The results are shown in Table 1 and Figure 5 . As shown in Table 1 and Figure 5 , the autonomous alternation behavior rate was lower in the medium control group than in the sham operation group, and a significant difference was observed (p < 0.01). The autonomous alternation behavior rate was higher in the extract A administration group than in the medium control group, and a significant difference was observed (p < 0.01). In addition, the autonomous alternation behavior rate was higher in the extract W administration group than in the medium control group, and a significant difference was observed (p < 0.05).

[0364] [Table 1]

[0365]

[0366] [Experiment c: Test as a deodorant]

[0367] [Preparation of extract]

[0368] The above extract A was dissolved in 20% ethanol to obtain an extract solution A having a solid content of 30% (w / w).

[0369] <Test Example cl: Deodorizing effect against isovaleric acid>

[0370] After the extract solution A 0.17 g was dissolved in 20% ethanol 1 mL, 1 mL of water was added to further dissolve it. To the dissolved solution 1 mL, water 9 mL was added to prepare a dissolved solution containing the extract solution A (dissolved solution (Al)).

[0371] In a centrifuge tube of 15 mL capacity, an aqueous solution of isovaleric acid 1 ppm (w / v) 10 mL and the dissolved solution (Al) 0.2 mL were added to prepare a sample solution (1) (final concentration of the extract solution A 0.017% (w / v)).

[0372] As a control, an aqueous solution of isovaleric acid 1 ppm (w / v) 10 mL and water 0.2 mL were prepared to prepare a control (1).

[0373] The degree of odor was evaluated by 10 panelists based on the following evaluation criteria for the sample solution (1) and the control (1), respectively.

[0374] 0: no odor

[0375] 1: a degree of barely perceptible

[0376] 2: a degree of easily perceptible

[0377] 3: a slightly strong odor

[0378] 4: a strong odor

[0379] The average of the scores was calculated to be 2.8 for the control (1) and 1.2 for the sample solution (1). A multiple comparison test by Bonferroni method was performed, and as a result, a significant difference was observed in the difference between these scores.

[0380] <Test Example cl: Deodorizing effect against isovaleric acid>

[0381] In a centrifuge tube of 15 mL capacity, an aqueous solution of isovaleric acid 1 ppm (w / v) 10 mL and the above dissolved solution (Al) 0.2 mL were added to prepare a sample solution (1) (final concentration of the extract solution A 0.017% (w / v)).

[0382] As a control, an aqueous solution of isovaleric acid 1 ppm (w / v) 10 mL and water 0.2 mL were prepared to prepare a control (1).

[0383] The degree of odor was evaluated by 10 panelists based on the following evaluation criteria for the sample solution (1) and the control (1), respectively.

[0384] The average of the scores was calculated, and as a result, the average of the control (2) was 2.78, and that of the sample liquid (2) was 1.8. A multiple comparison test by the Bonferroni method was performed, and as a result, a significant difference was observed in the difference in these scores.

[0385] <Experiment Example C3: Deodorizing effect against methyl mercaptan>

[0386] A sample liquid (3) (final concentration of the extract A 0.017% (w / v)) was prepared by adding 10 mL of an aqueous solution of 0.1 ppm of methyl mercaptan and 0.2 mL of the above-mentioned dissolved solution (Al) in a centrifugal tube of 15 mL capacity.

[0387] As a control, a mixture of 10 mL of an aqueous solution of 0.1 ppm (w / v) of methyl mercaptan and 0.2 mL of water was prepared (control (3)).

[0388] The degree of odor was evaluated by 9 panelists based on the same evaluation criteria as in Experiment Example Cl, with respect to the sample liquid (3) and the control (3), respectively.

[0389] The average of the scores was calculated, and as a result, the average of the control (3) was 3.11, and that of the sample liquid (2) was 2.41. A multiple comparison test by the Bonferroni method was performed, and as a result, a significant difference was observed in the difference in these scores.

[0390] <Experiment Example C4: Deodorizing effect against trimethylamine>

[0391] A sample liquid (4) (final concentration of the extract A 0.017% (w / v)) was prepared by adding 10 mL of an aqueous solution of 1 ppm (w / v) of trimethylamine and 0.2 mL of the above-mentioned dissolved solution (Al) in a centrifugal tube of 15 mL capacity.

[0392] As a control, a mixture of 10 mL of an aqueous solution of 1 ppm (w / v) of trimethylamine and 0.2 mL of water was prepared (control (4)).

[0393] The degree of odor was evaluated by 10 panelists based on the same evaluation criteria as in Experiment Example Cl, with respect to the sample liquid (4) and the control (4), respectively.

[0394] The average of the scores was calculated, and as a result, the average of the control (4) was 2.25, and that of the sample liquid (4) was 1.28. A multiple comparison test by the Bonferroni method was performed, and as a result, a significant difference was observed in the difference in these scores.

[0395] <Experiment Example C5: Deodorizing effect against diacetyl>

[0396] A sample solution (5) was prepared by adding 10 mL of a 2 ppm (w / v) aqueous solution of diacetyl and 0.2 mL of the above-mentioned dissolved solution (Al) in a centrifuge tube of 15 mL capacity.

[0397] As a control, a mixture of 10 mL of a 2 ppm (w / v) aqueous solution of diacetyl and 0.2 mL of water (control (5)) was prepared.

[0398] The degree of odor was evaluated by 9 panelists based on the same evaluation criteria as in Test Example cl for the sample solution (5) and the control (5), respectively.

[0399] The average of the scores was calculated, and as a result, the average was 2.78 for the control (5) and 1.67 for the sample solution (5). A multiple comparison test by Bonferroni method was performed, and as a result, a significant difference was observed in the difference between these scores.

[0400] < Test Example c6: Deodorizing effect on nonenal >

[0401] A sample solution (6) was prepared by adding 10 mL of a 0.01 ppm (w / v) aqueous solution of nonenal and 0.4 mL of the above-mentioned dissolved solution (Al) in a centrifuge tube of 15 mL capacity (final concentration of the extract A: 0.034% (w / v)).

[0402] As a control, a mixture of 10 mL of a 0.01 ppm (w / v) aqueous solution of nonenal and 0.4 mL of water (control (6)) was prepared.

[0403] The degree of odor was evaluated by 11 panelists based on the same evaluation criteria as in Test Example cl for the sample solution (6) and the control (6), respectively.

[0404] The average of the scores was calculated, and as a result, the average was 2.42 for the control (6) and 1.45 for the sample solution (6). A multiple comparison test by Bonferroni method was performed, and as a result, a significant difference was observed in the difference between these scores.

[0405] < Test Example c7: Deodorizing effect on ammonium mercaptoacetate >

[0406] A sample solution (7) was prepared by adding 10 mL of a 0.85% (w / v) aqueous solution of ammonium mercaptoacetate and 0.4 mL of the above-mentioned dissolved solution (Al) in a centrifuge tube of 15 mL capacity (final concentration of the extract A: 0.034% (w / v)).

[0407] As a control, a mixture of 10 mL of a 0.85% (w / v) aqueous solution of ammonium mercaptoacetate and 0.4 mL of water (control (7)) was prepared.

[0408] The degree of odor was evaluated by 10 panelists based on the same evaluation criteria as in Test Example cl for the sample solution (7) and the control (7), respectively.

[0409] The average of the scores was calculated, and as a result, the control (7) was 3.08 in average and the sample solution (7) was 1.83. A multiple comparison test by Bonferroni method was performed, and as a result, a significant difference was observed in the difference of these scores.

[0410] < Test Example c8: Deodorizing effect against monoethanolamine thioglycolate>

[0411] A sample solution (8) (final concentration of the extract A 0.034% (w / v)) was prepared by adding 10 mL of a 0.085% (w / v) aqueous solution of monoethanolamine thioglycolate and 0.4 mL of the above-mentioned dissolved solution (Al) in a 15 mL capacity centrifuge tube.

[0412] As a control, a mixture of 10 mL of a 0.085% (w / v) aqueous solution of monoethanolamine thioglycolate and 0.4 mL of water (control (8)) was prepared.

[0413] The degree of odor was evaluated by 10 panelists based on the same evaluation criteria as in Test Example cl for the sample solution (8) and the control (8), respectively.

[0414] The average of the scores was calculated, and as a result, the control (8) was 3.3 in average and the sample solution (8) was 2.38. A multiple comparison test by Bonferroni method was performed, and as a result, a significant difference was observed in the difference of these scores.

[0415] < Test Example c9: Deodorizing effect against smoke>

[0416] After 0.17 g of the extract A was dissolved in 1 mL of 20% ethanol, 1 mL of water was added to further dissolve it. To 0.3 mL of the dissolved solution, 30 mL of water was added to prepare a dissolved solution containing the extract A (dissolved solution (A2)).

[0417] A 5 L capacity Erlenmeyer flask was inverted, and a lit cigarette was put about 5 cm into the mouth of the Erlenmeyer flask to capture the smoke of the cigarette for about 30 to 40 seconds. Three pieces of 10 cm x 10 cm cloth (cotton towel) were put into the Erlenmeyer flask in which the smoke was captured, and the flask was quickly sealed with a plug while the cloth was allowed to absorb the smoke by shaking the flask. After 5 minutes, the towels were taken out as test cloths.

[0418] After the dissolved solution (A2) was sprayed onto the test cloths 5 times (0.15 ml x 5 times = about 0.75 ml) using a sprayer, it was kneaded well to make it uniform, and this was used as a sample (9).

[0419] As a control, a sample (control (9)) in which water spray was performed 5 times (about 0.75 ml) to the test cloth was prepared.

[0420] The degree of odor was evaluated by 9 panelists based on the same evaluation criteria as in Test Example cl for the sample (9) and the control (9), respectively.

[0421] The average of the scores was calculated, and as a result, the control (9) was 1.89 and the sample (9) was 0.61. By the multiple comparison test of Bonferroni method, a significant difference was observed in the difference of these scores.

[0422] [Experiment d: Test as an anti-aging agent]

[0423] [Experiment Example dl: MMP-1 production inhibition test]

[0424] The MMP-1 production inhibition effect of the extract A and the extract W was investigated by evaluating the inhibitory effect of MMP-1 on normal human fibroblasts.

[0425] [Experiment Example dl-1]

[0426] As a culture medium for culturing normal human fibroblasts, Dulbecco's modified MEM medium containing 5% calf serum (manufactured by KURABO INDUSTRIES LTD., hereinafter also referred to as "5% FBS-DMEM medium") was used. A culture medium containing the extract A in the concentration of Table 2 in the 5% FBS-DMEM medium was prepared, and this was used as a test sample-containing culture medium.

[0427] Normal human fibroblasts (manufactured by KURABO INDUSTRIES LTD.) were seeded at a density of 2.0 x 10 4 cells / well in a 96-well microplate. After 24 hours from the seeding, the above-mentioned 5% FBS-DMEM in the microplate was replaced with a test sample-containing culture medium containing the extract A. After the medium replacement, further culture was performed for 24 hours, and then the test sample-containing culture medium was replaced with HANKS buffer (containing Ca 2+ and Mg 2+ , HBS(+)). Then, fresh test sample-containing culture medium was immediately replaced, and further culture was performed for 24 hours. After the culture, the culture supernatant was recovered and subjected to ELISA.

[0428] ELISA was performed using a sandwich method, and was carried out using the following method. After adding anti-human MMP-1 antibody to a high-adsorption ELISA well plate, coating was performed overnight at room temperature, and then, blocking was performed for 1 hour using 1% bovine albumin (BSA). After blocking, culture supernatant and MMP-1 for a standard curve were added, and incubation was performed for 2 hours at room temperature, and then, anti-human MMP-1 biotinylated antibody was added, and incubation was performed for 1.5 hours at room temperature. Further, streptavidin HRP was added, and incubation was performed for 30 minutes at room temperature. Next, phosphoric acid-citric acid buffer (0.1 mol / L, pH 4.0) containing 0.3 mg / mL of 2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid)-diammonium salt (ABTS) and 0.03% (V / V) of hydrogen peroxide was added, and reaction was performed for 20 minutes, and absorbance at 405 nm was measured using a microplate reader.

[0429] The amount of MMP-1 in the culture supernatant was calculated from a standard curve prepared using commercially available MMP-1. On the other hand, the cells after culture were dissolved using 0.5% (V / V) of trinitrobenzene X-100 buffer, and the total protein amount was quantified using the BCA method. The amount of MMP-1 production per unit protein amount was calculated by dividing the amount of MMP-1 in the culture supernatant by the total protein amount in the cells. The results are shown in Table 2.

[0430] [Experimental Example d1-2]

[0431] In Experimental Example d1-1, the culture medium containing the test sample was replaced with HANKS buffer (containing Ca 2+ , Mg 2+ , HBS(+)), and immediately after irradiation with ultraviolet A wave (UVA) at a dose of 4 J / cm 2 , fresh culture medium containing the test sample was added, and otherwise, the amount of MMP-1 production per unit protein amount was calculated using the same method as in Experimental Example d1-1. The results are shown in Table 2.

[0432] [Experimental Example d1-3]

[0433] In Experimental Example d1-2, extract A was replaced with extract W, the dose of ultraviolet A wave was changed to 5 J / cm 2 , and otherwise, the amount of MMP-1 production per unit protein amount was calculated using the same method as in Experimental Example d1-2. The results are shown in Table 2.

[0434] [Table 2]

[0435]

[0436] 1) Significant difference in Experimental Example for the concentration of extract A or extract W of 0 μg / mL

[0437] *: p < 0.05, significant decrease

[0438] <Example d2: Elastase activity inhibition test>

[0439] The elastase activity inhibition effects of Extract A and Extract W were investigated by evaluating the normal human fibroblast-derived elastase activity inhibition.

[0440] [Example d2-1]

[0441] A confluent normal human fibroblast cell was maintained in a 10 cm 2 dissolved by adding 0.5% (V / V) of trinitrobenzene X-100 buffer (1 mmol / L PMSF, 100 mmol / L Tris hydrochloride buffer, pH 8.0) to the cell, and used as a crude enzyme solution of fibroblast-derived elastase. As a substrate for elastase, succinyl-L-alanyl-L-alanyl-L-alanine-p-nitroaniline (Suc-Ala-Ala-Ala-pNA, 5 mmol / L, manufactured by BACHEM AG) was used. As a test solution, Extract A was dissolved in Tris buffer to obtain a test solution of a prescribed concentration. As a positive control, 6.25 mmol / L of EDTA was used.

[0442] The test solution was added to each well of a 96-well microplate in 50 μL. In addition, 100 mmol / L of Tris hydrochloride buffer (pH 8.0) containing 5 mmol / L of Suc-Ala-Ala-Ala-pNA was prepared, and 100 μL was added to each well. A reaction solution was obtained by adding 50 μL of the crude enzyme solution of elastase to each well. The absorbance at 405 nm of the reaction solution immediately after the addition of the crude enzyme solution of elastase was measured as the absorbance before the reaction (blank absorbance). Subsequently, the absorbance at 405 nm of the reaction solution after allowing it to react at 37°C for 2 hours was measured (absorbance after the reaction). Using the value obtained by subtracting the blank absorbance from the absorbance after the reaction, the absorbance when the test solution was not added was taken as C', and the absorbance when the test solution was added was taken as S', and the elastase activity inhibition rate (%) was calculated using the following equation. The results are shown in Table 3. Extract A showed a significant elastase activity inhibition effect by p < 0.05.

[0443] Elastase inhibition rate (%) = (1 - (S' / C')) x 100

[0444] [Example d2-2]

[0445] Using the same method as in Test Example d2-1, the elastase activity inhibition rate of Extract W was obtained, except that Extract A was replaced with Extract W. Note that, as a positive control, 12.25 mmol / L of EDTA was used. An elastase activity inhibitory effect was also observed for Extract W.

[0446] [Table 3]

[0447]

[0448] 2) Significant difference in Test Example for the concentration of Extract A of 0 μg / mL

[0449] *: p < 0.05, significant decrease

[0450] [Test Example d3: Fibroblast activation test]

[0451] The activation effect of Extract A on fibroblasts was investigated using the MTT method.

[0452] As a culture medium for culturing normal human fibroblasts, the same cells as in Test Example d1 were used. Extract A was dissolved in water, and a culture medium containing Extract A at the concentrations in Table 4 in 1% FBS-DMEM culture medium was prepared, and used as a test sample-containing culture medium. As a positive control, a 5% FBS-DMEM culture medium was used.

[0453] Normal human fibroblasts (manufactured by KURABO INDUSTRIES LTD.) were seeded at a density of 2.0 x 10 4 cells / well in a 96-well microplate together with a 5% FBS-DMEM culture medium. After 24 hours from seeding, the above-mentioned 5% FBS-DMEM culture medium in the microplate was replaced with a test sample-containing culture medium containing Extract A. After further culturing for 48 hours after replacing the culture medium, a 1% FBS-DMEM culture medium containing 0.4 mg / mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added, and cultured for 2 hours. The culture medium was removed, and blue formazan generated by adding 2-propanol was extracted. The absorbance at 550 nm of the extract was measured as the amount of blue formazan. The ratio (percentage) of the amount of blue formazan when Extract A was used to the amount of blue formazan when the concentration of Extract A (based on the total amount of the test sample-containing culture medium) was 0 μg / mL (control) was calculated as the cell activation rate. The greater the value of the cell activation rate, the higher the cell activation effect can be said to be. The results are shown in Table 4.

[0454] [Table 4]

[0455] [Table 4]

[0456] 3) Significant difference for the concentration of Extract A of the test example

[0457] *: p < 0.05, significant decrease

[0458] [Experiment e: Test as an anti-glycation agent]

[0459] [Anti-glycation activity evaluation of Extract A (Test examples el ~ e2)]

[0460] [Test example el: Evaluation of anti-glycation activity in a human serum albumin model]

[0461] The anti-glycation activity (AGEs production inhibitory action) of a decomposition extract of bagasse (Extract A) on AGEs produced by a glucose-human serum albumin (HSA) reaction was investigated.

[0462] (Sample preparation)

[0463] Extract A, which is a decomposition extract of bagasse, was dissolved in distilled water to be 100 mg / mL to obtain a test solution stock. The test stock solution was diluted with distilled water to obtain a solution of 0.01 to 100 mg / mL. This was used as a sample for the test. As a positive control, an aqueous solution of aminoguanidine (concentration 3.0 mg / mL) as a glycation reaction inhibitor was obtained.

[0464] (Glycation reaction conditions)

[0465] Each concentration of the sample prepared was added to a reaction solution containing 0.1 mol / L phosphate buffer (pH 7.4), 8 mg / mL human serum albumin (HSA, manufactured by Sigma-Aldrich Corporation), and 0.2 mol / L aqueous glucose solution so as to be 1 / 10 of the concentration (final concentration of the reaction), and incubated at 60°C for 40 hours. Instead of the sample as a negative control, a sample to which distilled water was added was used. As a positive control, the above-described aqueous aminoguanidine solution was used. Note that, as a blank with respect to the positive control, a sample to which distilled water was added was used instead of glucose.

[0466] (Determination of anti-glycation activity)

[0467] After the saccharification reaction was completed, the fluorescent AGEs produced in the reaction solution were measured using a microplate reader (SpectraMax i3, Molecular Devices) (excitation wavelength 370 nm, fluorescence wavelength 440 nm). The AGE production inhibition rate (hereinafter referred to as "inhibition rate") was calculated according to the following formula: the fluorescence intensity of the reaction solution containing the sample during the saccharification reaction was defined as F1; the fluorescence intensity of the reaction solution incubated with distilled water instead of the aqueous glucose solution was defined as F2; ​​the fluorescence intensity of the reaction solution incubated without the addition of a decomposed extract of sugarcane bagasse or aminoguanidine was defined as F3; and the fluorescence intensity of the reaction solution incubated without the addition of a decomposed extract of sugarcane bagasse or aminoguanidine and with distilled water instead of the aqueous glucose solution was defined as F4, as a blank.

[0468] Fluorescent AGEs inhibition rate (%) = (1-(F1-F2) / (F3-F4)) × 100

[0469] The inhibition rate of fluorescent AGEs (HSA) at each final reaction concentration (0.1 mg / mL, 0.3 mg / mL or 1 mg / mL) of the decomposed extract of bagasse (extract A) is shown in FIG. Figure 6 .like Figure 6 As shown, the inhibition rate of extract A increased in a concentration-dependent manner, indicating anti-glycation activity (inhibitory effect on the production of fluorescent AGEs (HSA)). The inhibition rate of fluorescent AGEs (HSA) in 0.3 mg / mL of aminoguanidine as a positive control was 81.2±1.4%. It was confirmed that aminoguanidine has anti-glycation activity (inhibitory effect on the production of fluorescent AGEs (HSA)). The IC calculated from the inhibition rate of the samples at each concentration of extract A was 50 The (50% inhibition concentration) was 0.19 mg / mL, and extract A was shown to have anti-glycation activity in the human serum albumin model.

[0470] [Test Example e2: AGEs cross-linking cleavage test (Evaluation of AGEs decomposition activity)]

[0471] Next, the AGE-degrading activity of the sugarcane bagasse extract (Extract A) was evaluated using an AGE cross-link cleavage test. The AGE-degrading activity (AGE cross-link cleavage) was evaluated using a known method (e.g., Glycative Stress Research 2015, Vol. 2 (No. 2), pp. 58-66) using 1-phenyl-1,2-propanedione (PPD), which has an α-diketone structure, as a model substrate.

[0472] (Sample Preparation)

[0473] The extract A, which is a decomposition extract of bagasse, was dissolved in distilled water to make 20 mg / mL to obtain a sample for the test.

[0474] (Cross-linking cleavage reaction conditions)

[0475] The sample prepared in the above was added to a reaction solution composed of 0.16 mol / L of a phosphate buffer (pH 7.4), 2 mmol / mL of PPD so as to become 1 / 2 concentration (10 mg / mL), and incubated at 37°C for 8 hours. As a negative control, a sample to which distilled water was added was used instead of the sample. As a positive control, N-phenacylthiazolium bromide (PTB) was used. The reaction solution was centrifuged at 20°C, 3000 x g for 10 minutes to obtain a supernatant. The amount of benzoic acid in the supernatant was analyzed by reverse phase HPLC. The amount of benzoic acid in the reaction solution was calculated by subtracting the amount of benzoic acid in the sample measured separately. Since 1 mol of PPD generates 1 mol of benzoic acid, the cross-linking cleavage rate was calculated from the following equation.

[0476] Cross-linking cleavage rate (%) = {(A-B) / C} x 100

[0477] A: Amount of benzoic acid in the reaction solution

[0478] B: Amount of benzoic acid in the sample

[0479] C: Amount of PPD supplied to the reaction (substrate amount)

[0480] (Cross-linking cleavage test results)

[0481] The cross-linking cleavage rate in the sample and PTB solution (5 mmol / L), and the value of the cross-linking cleavage rate in the sample when PTB (5 mmol / L) is set to 100% (cleavage rate relative value) were calculated, and as a result, the cross-linking cleavage rate of the sample was 8.50, the cross-linking cleavage rate of PTB was 20.1, and the cleavage rate relative value of the sample was 42.29%. Therefore, it was shown that the extract A has AGEs decomposition activity.

[0482] [Anti-glycation activity evaluation of extract W (test examples e3-e4)]

[0483] [Test example e3: Evaluation of anti-glycation activity in human serum albumin model]

[0484] As a decomposition extract of sugar cane bagasse, the extract W described above was used, dimethyl sulfoxide (DMSO) was used instead of distilled water in the preparation of the sample, and otherwise, the anti-glycation activity was evaluated in the same manner as in Test Example el. As a positive control, an aqueous solution of aminoguanidine (final concentration 0.3 mg / mL) was used. The inhibition rate of fluorescent AGEs (HSA) in 0.3 mg / mL of aminoguanidine as a positive control was 74.6 ± 0.8%. The determination results are shown in Table 1. Figure 7 In addition, the IC50 (50% generation inhibition concentration) calculated from the inhibition rate of the sample in each concentration of the extract W was 0.14 mg / mL, showing that the extract W had the anti-glycation activity. 50

[0485] [Test Example e4: AGEs cross-linking cleavage test (evaluation of AGEs decomposition activity)]

[0486] (Sample preparation)

[0487] The extract W as a decomposition extract of sugar cane bagasse was dissolved with 50% DMSO to obtain a 20 mg / mL solution. The solution was gradient-diluted with 50% DMSO to be used as a sample for the test. As a positive control, a 10 mmol / L solution of N-phenacylthiazolium bromide (PTB) was used.

[0488] (Cross-linking cleavage reaction conditions)

[0489] The test solution or the PTB solution (10 mmol / L) was mixed with 10 mmol / L of a PPD solution and 0.2 mol / L of a phosphate buffer (pH 7.4) at a ratio of 5:1:4, and reacted at 37°C for 8 hours (n = 3). After the reaction was completed, the reaction was stopped by adding hydrochloric acid. Then, the reaction solution was centrifuged at 3000 x g for 10 minutes at 20°C, and the amount of benzoic acid in the supernatant was analyzed by reverse phase HPLC. The amount of benzoic acid in the reaction solution was obtained by subtracting the amount of benzoic acid in the sample measured separately. Since 1 mol of PPD generates 1 mol of benzoic acid, the cross-linking cleavage rate was calculated using the following formula. The relative value of the cross-linking cleavage (relative value of the cleavage rate) is the value (%) of the cross-linking cleavage rate at each concentration when the cross-linking cleavage rate of PTB is set to 100. Note that, as a measuring device, a Shimadzu ultra-high performance liquid chromatograph Nexera system (manufactured by Shimadzu Corporation) was used.

[0490] Cross-linking cleavage rate (%) = {(A - B) / C} x 100

[0491] A: Amount of benzoic acid in the reaction solution

[0492] B: Amount of benzoic acid in the sample ​

[0493] C: Amount of PPD supplied to the reaction (amount of substrate)

[0494] (Crosslinking breakage test results)

[0495] The crosslinking breakage rate in the sample and PTB solution (5 mmol / L) and the value of the crosslinking breakage rate in the sample when PTB (5 mmol / L) is taken as 100% (breakage rate relative value) were found, and as a result, the crosslinking breakage rate of the sample was 10.07, the crosslinking breakage rate of PTB was 22.4, and the breakage rate relative value of the sample was 44.87%. Thus, it was shown that the extract W has AGEs decomposition activity.

[0496] [Experiment f: Test as an anti-type I allergy agent]

[0497] [Experiment fl: RBL-2H3 cell degranulation inhibition test based on extract A]

[0498] [Preparation of test solution]

[0499] The extract A was dissolved in water to obtain a test solution stock solution of 50 mg / mL. The test solution stock solution was diluted with the buffer solutions shown in Table 5 below, and test solutions of 2000, 1000, and 500 μg / mL in the concentration to be tested were prepared.

[0500] [Operation of test]

[0501] After RBL-2H3 cells (National Institute of Biomedical Innovation, Health and Nutrition) which are rat basophilic leukemia cells were inoculated in a 96-well plate, they were incubated overnight. After a medium having the composition shown in Table 5 and containing anti-DNP-IgE antibody was added, the cells were washed with a buffer solution after being reacted at 37°C for 2 hours. Further, the test solutions prepared at 2000, 1000, and 500 μg / mL were added at a final concentration of 1000 μg / mL (Example fl), 500 μg / mL (Example f2), and 250 μg / mL (Example f3), respectively. Then, after being reacted at 37°C for 10 minutes, DNP-labeled human serum albumin was added, and further reacted at 37°C for 3 hours. In addition, a sample to which no test solution was added but only the buffer solution was added was used as an untreated control (Comparative Example fl), and a sample to which wortmannin (Wako Pure Chemical Industries, Ltd.) was added at a final concentration of 25 nmol / L was used as a positive control, and the test was performed in the same manner. Further, after a medium not containing anti-DNP-IgE antibody was added, the buffer solution and DNP-labeled human serum albumin were sequentially added, and a sample obtained by reacting in the same manner was used as an antigen-unstimulated control.

[0502] After the total amount of the cell supernatant was taken into the empty wells, a lysis buffer was added to the cells, and the mixture was left to stand at room temperature for 10 minutes to obtain a cell lysate. To the cell supernatant and the cell lysate, a p-nitrophenyl-2-acetamide-2-deoxy-β-D-glucoside solution (hereinafter referred to as a substrate solution) was added, respectively, and the mixture was left to react at 37°C for 25 minutes. Then, glycine buffer was added to stop the reaction. Separately, glycine buffer was added to the cell supernatant and the cell lysate, respectively, and the mixture was left to react at 37°C for 25 minutes. Then, the sample to which the substrate solution was added was used as a sample blank.

[0503] [Table 5]

[0504]

[0505] [Calculation of degranulation rate]

[0506] For each of the samples of Examples fl to f3, Comparative Example fl, the positive control, the antigen-unstimulated control, and the sample blank, the absorbance of p-nitrophenol produced by the reaction of β-hexosaminidase present in the granules with the substrate was measured using a spectrometer (SpectraMax M2e, Molecular Devices Corporation) (measurement wavelength: 405 nm, control wavelength: 650 nm).

[0507] From the absorbance of each sample relative to the absorbance of Comparative Example fl, the release rate was calculated using the following equation, and the degranulation rate was calculated from the release rate. Note that, in the equation, the "absorbance on the cell supernatant side" and the "absorbance on the cell lysate side" are values obtained by subtracting the sample blank.

[0508] Release rate (%) = absorbance on the cell supernatant side / (absorbance on the cell supernatant side + absorbance on the cell lysate side)

[0509] Degranulation rate (%) = {(average of release rates of test solutions - release rate of antigen-unstimulated control) / (release rate of untreated control - release rate of antigen-unstimulated control)} x 100

[0510] The results of the calculation of the degranulation rate are shown in Figure 8 For the degranulation rate, Comparative Example fl was 100 ± 11.5, the positive control was 39 ± 8.4, Example fl was 49 ± 12.5, Example f2 was 61 ± 11.2, and Example f3 was 77 ± 11.1.

[0511] [Experiment f2: RBL-2H3 cell degranulation inhibition test based on extract W]

[0512] [Preparation of test solution]

[0513] The extract W was dissolved in ethanol to obtain a test solution stock solution at 50 mg / mL. The test solution stock solution was diluted with the buffer solutions shown in Table 5 above to prepare test solutions at a concentration of 1000, 500 and 250 μg / mL.

[0514] [Degranulation inhibition test of RBL-2H3 cells]

[0515] Using the test solution containing the prepared extract W, the test operation in the above-described Test Example fl was performed in such a manner that the test solution was added at a final concentration of 500 μg / mL (Example f4), 250 μg / mL (Example f5) and 125 μg / mL (Example f6) of the test solution, and otherwise the degranulation rate was calculated by the same method as in Test Example 1. Comparative Example fl is the same untreated control as in Test Example fl.

[0516] The results of the calculation of the degranulation rate are shown in Figure 9 . As for the degranulation rate, Comparative Example fl was 100 ± 2.9, while Example f4 was 12 ± 1.6, Example f5 was 47 ± 4.9 and Example f6 was 80 ± 6.1.

[0517] [Test g: Test as an antihypertensive agent]

[0518] [Angiotensin converting enzyme inhibition test]

[0519] An angiotensin converting enzyme inhibition test was performed based on the method of Nakano et al. (Nakano et al., Biosci. Biotechnol. Biochem., 70, 1118-1126 (2006)).

[0520] After 1.0 g of each of the extract A and the extract W was extracted with 20 ml of 50% (V / V) ethanol solution, the test solutions shown in Table 6 were prepared by diluting with 0.1 mol / L Hepes buffer (pH 8.3) to the concentrations shown in Table 6. 25 μL of the 0.1 mol / L Hepes buffer (untreated area) or the test solution was added to a 96-well microplate, and further 25 μL of 20 mU / mL ACE solution was added, and incubated at 37°C for 5 minutes. Further, 25 μL of 8 mmol / L substrate (hippuryl-L-histidyl-L-leucine; Hip-His-Leu) solution was added, and reacted at 37°C for 30 minutes. Then, 25 μL of 0.1 mol / L sodium hydroxide aqueous solution was added to stop the reaction, and further 25 μL of 1 mass% o-phenylenediamine (OPA) aqueous solution was added, and left for 20 minutes. Then, 25 μL of 0.1 mol / L hydrochloric acid was added as a test solution for measurement. The test solution for measurement was left at room temperature for 10 minutes, and the fluorescence intensity was measured using a microplate reader under the following conditions. Note that, in the blank, instead of the ACE solution, a phosphate buffer physiological saline was used.

[0521] (Microplate reader operation conditions)

[0522] Model: SpectraMax M2e (manufactured by Molecular Devices Corporation)

[0523] Measurement conditions: fluorescence, end-point mode, bottom reading

[0524] Excitation wavelength: 355 nm

[0525] Fluorescence wavelength: 460 nm

[0526] The fluorescence intensity of each test solution was evaluated as the ACE inhibition rate when the fluorescence intensity of the untreated area was taken as 100%. The results are shown in Table 6.

[0527] [Table 6]

[0528]

[0529] As shown in Table 6, the ACE inhibitory effect was observed in the extract A and the extract W. The IC50 of the extract A was 0.95 mg / mL (final concentration in the total amount of the test solution for measurement: 0.16 mg / mL), and the IC50 of the extract W was 0.52 mg / mL (final concentration in the total amount of the test solution for measurement: 0.087 mg / mL). 50 The IC50 of the extract W was 0.52 mg / mL (final concentration in the total amount of the test solution for measurement: 0.087 mg / mL). 50 The IC50 of the extract W was 0.52 mg / mL (final concentration in the total amount of the test solution for measurement: 0.087 mg / mL).

[0530] [Experiment h: Test as a flavor improver]

[0531] [Experiment Example h1: Flavor improvement test based on extract A]

[0532] [soy milk]

[0533] A solution of extract A (solid content concentration 0.3%) was added to 0.6 g (Example h1-1) or 0.3 g (Example h1-2) of soy milk (trade name: Sugoii Daizu no Jikken-gata, manufactured by Otsuka Chilled Foods Co., Ltd.) 100 g in such a manner that extract A became the concentration shown in Table 7, to prepare test products (Examples h1-1, h1-2).

[0534] [beverage containing vinegar]

[0535] A solution of extract A (solid content concentration 0.3%) was added to 1.7 g of a beverage containing vinegar prepared from rice vinegar 50 g, water 200 g, and granulated sugar 15 g, to prepare a test product (Example h1-3).

[0536] [beef processed product (meatball)]

[0537] A solution of extract A (solid content concentration 0.3%) was added to 0.012 g of beef 30 g, and the mixture was prepared using a food processor while the beef was made into a meat paste. The meat paste was divided into 10 g each in an aluminum foil case, and baked in an oven at 200°C for 5 minutes, and then inverted and baked for another 5 minutes. The test product (Example h1-4) was cooled to the extent of human skin after baking.

[0538] [chicken processed product (chicken ball)]

[0539] Chicken breast 25 g, soy protein (trade name: New Soyime S20F, manufactured by Nisshin OilliO Group, Ltd.) reconstituted with water 10 g, and a solution of extract A (solid content concentration 0.3%) 0.1 g were mixed. The mixture was cut into small pieces and heated in boiling water for 5 minutes, and the prepared chicken balls were used as a test product (Example h1-5).

[0540] [organoleptic evaluation]

[0541] The items shown in Tables 7 to 10 were subjected to sensory evaluation with respect to the food and drink of each of the examples. Note that the evaluation criteria for the sensory evaluation were relative evaluations compared with a control (not containing the extract A), and each of the evaluations of the examples was evaluated with a value between -2 points and 2 points when the control was set to 0 points. With respect to each of the evaluation items, -2 points means "the flavor is least felt compared with the control" and 2 points means "the flavor is most felt compared with the control". The average of the scores is shown in Tables 7 to 10. Note that "solid content concentration" in the table indicates the solid content concentration of the extract A in the total amount of the test product, and the same applies hereinafter unless otherwise specified.

[0542] [Table 7]

[0543]

[0544] [Table 8]

[0545]

[0546] [Table 9]

[0547]

[0548] [Table 10]

[0549]

[0550] [Example h2: Flavor improvement test based on extract W]

[0551] [soy milk, beverage containing vinegar, beef processed product (meat ball)]

[0552] In Example h2, the extract A was changed to the extract W, and otherwise the same as in Example h1 to obtain the test product (Examples h2-1 to h2-3).

[0553] [processed seafood (grilled mackerel)]

[0554] An impregnation solution of 4.175 g of a solution (solid content concentration 0.3%) of the extract W added to 500 g of 8% brine was prepared. After thawing the frozen mackerel fillets, the skin was cut to make incisions and then impregnated in the impregnation solution for 10 minutes. The mackerel was grilled with a grill for 7 minutes on both sides to prepare the test product (Example h2-4). With respect to the test product, the temporarily frozen test product was heated with a microwave oven and then subjected to sensory evaluation.

[0555] [lactic acid bacteria beverage]

[0556] A lactic acid bacterium beverage was prepared which contained 100 parts by mass of a commercially available beverage (trade name: Millmill, manufactured by Yakult Company), 0.275 parts by mass of 10% acetic acid, 0.007 parts by mass of aspartame (manufactured by Ajinomoto Co., Inc.), and 0.015 parts by mass of a 1% solution of β-carotene (manufactured by Mitsubishi-Chemical Foods Corporation). A solution of extract W (solid content concentration 0.3%) was added at 0.075 g to 100 g of this lactic acid bacterium beverage to prepare a test product (Example h2-5).

[0557] Sensory evaluations were performed on each item using the same method as in Test Example hi. The results are shown in Tables 11 to 15. Note that in Table 11, the solid content concentration in the table indicates the solid content concentration of extract W in the total amount of the impregnation solution.

[0558] [Table 11]

[0559]

[0560] [Table 12]

[0561]

[0562] [Table 13]

[0563]

[0564] [Table 14]

[0565]

[0566] [Table 15]

[0567]

[0568] [Table 15]

[0567]

[0568] <Test Example h3: Comparative Test with Extract Derived from Sugarcane>

[0569] [Manufacture of Extract Derived from Sugarcane]

[0570] 7500 L of raw sugarcane juice (washed juice obtained from lime washing in the sugar production process of a raw sugar production plant, produced in Okinawa, solid content 14%) was filtered using a cartridge filter (Advantech Co., Ltd., cotton wound filter element, model TCW-10-CSD) to obtain a washed juice filtration product. 500 L of synthetic adsorbent (Mitsubishi Chemical Corporation, SP-207) was packed in a resin column (800 mm inner diameter, 2000 mm height), and the washed juice filtration product was passed through the column at a flow rate of 2500 L / hour (SV = 5.0 (hours)). -1 )) passed. The elution pattern is shown in Figure 10 . Figure 10 (A) is the starting point of liquid flow. It should be noted that during the process of the washing juice passing through, 80°C water is continuously circulated in the water jacket.

[0571] Then, 1200 L of tap water was added at a flow rate of 2500 L / hour (SV = 5.0 (hour) -1 )) Cleaning is carried out through a resin tower. Figure 10 (B) is the starting point of the liquid flow. After washing with tap water, the fraction eluted from the resin column was tested for column stability. The results showed that the Bx was approximately 0 using a handheld sugar content (Bx) meter (manufactured by ATAGO CO., LTD., PAL-J model). Then, 1500 L of tap water was added at a flow rate of 4500 L / hour (SV = 9.0 (hours)). -1 )) passes through the bottom of the resin tower for backwashing.

[0572] Next, 1000 L of 55% ethanol aqueous solution (ethanol / water = 55 / 45 (volume / volume)) as an elution solvent was added at a flow rate of 1000 L / hour (SV = 2.0 (hour)). -1 ))Through the resin tower. Figure 10 (C) is the starting point of the liquid flow. Then, 760L of tap water is passed through the -1 )) Passed through the resin column to elute the components adsorbed on the synthetic adsorbent. It should be noted that a 55% ethanol aqueous solution and tap water were heated to 50°C using a plate heat exchanger (Hitachi, Ltd., RX-025A-KNHJR-36 model) and passed through the resin column.

[0573] The second half of the fraction eluted from the resin column, 1460 L ( Figure 10The fraction (a) was concentrated under reduced pressure to approximately 50 times its concentration and then freeze-dried overnight to obtain 8.4 kg of a dark brown powder (I). This powder was dissolved in ethanol and water to obtain a sugarcane-derived extract having a solids concentration of 30% by mass (hereinafter also referred to as "sugarcane extract").

[0574] [Soy milk, vinegar-containing beverages, processed beef products (meatballs), processed seafood (grilled mackerel), lactic acid bacteria beverages]

[0575] A control sample was prepared using the aforementioned sugarcane extract dilution (0.3% solids concentration) using the method described in Table 16. Meanwhile, for Examples h3-1 to h3-4 and Examples h3-7 to h3-8 (soy milk, vinegar-containing beverage, and grilled mackerel), test samples were prepared using the same method as in Test Example h1 or Test Example h2. For Examples h3-5 to h3-6 and Examples h3-9 to h3-10 (meatballs and lactic acid bacteria beverage), test samples were prepared using the control sample preparation method described in Table 16, except that the sugarcane extract dilution was replaced with a solution of Extract A or a solution of Extract W (0.3% solids concentration), respectively.

[0576] [Table 16]

[0577]

[0578] Sensory evaluation was conducted for each item using the same method as in Test Example h1, with the control (food and drink containing sugarcane extract) scored 0 and the evaluation for each example ranging from -2 to 2 points. The results are shown in Tables 17 to 21.

[0579] [Table 17]

[0580]

[0581] [Table 18]

[0582]

[0583] [Table 19]

[0584]

[0585] [Table 20]

[0586]

[0587] [Table 21]

[0588]

[0589] <Test Example h4: Evaluation Using a Smell Recognition Device>

[0590] The above extract A and the sugar cane extract were added to 0.2% acetic acid aqueous solution to prepare 0.2% acetic acid aqueous solutions having a final solid content concentration of 45 mass ppm, 90 mass ppm, and 180 mass ppm (Examples h4-1 to h4-3, Comparative Examples h4-1 to h4-3). The sourness of the acetic acid solutions was measured using a taste recognition device (TS-5000Z, manufactured by Intelligent Sensor Technology, Inc.). When measured using the taste recognition device, the measurement was performed by the first taste (relative value) of the sourness sensor (CAO). The relative values of the sourness of each acetic acid aqueous solution, with the sourness of the acetic acid aqueous solution to which no extract A and sugar cane extract were added (control) being set to 0, are shown in Table 22. A case where the relative value of the sourness was 0 or less showed a decrease in the unpleasant taste (sourness) caused by acetic acid compared with the 0.2% acetic acid aqueous solution as a control.

[0591] [Table 22]

[0592]

[0593] [Experiment i: Test as a muscle enhancer]

[0594] [Materials]

[0595] In the following test examples, the following materials shown below were used.

[0596] (Cell)

[0597] Mouse myoblast C2C12 cells (ATCC, CRL-1772)

[0598] (Culture medium)

[0599] Composition of proliferation culture medium: addition of DMEM medium, 10% FBS, antibiotic

[0600] Composition of differentiation culture medium: addition of DMEM medium, 0.5% FBS, antibiotic

[0601] (Test reagent)

[0602] Dulbecco's modified Eagle's medium (DMEM medium, Nacalai Tesque Co., Ltd.)

[0603] Fetal bovine serum (FBS) (Cell Culture Bioscience Co., Ltd.)

[0604] Penicillin-streptomycin mixed solution (Nacalai Tesque Co., Ltd.)

[0605] 0.25% trypsin / EDTA mixed solution (Nacalai Tesque Co., Ltd.)

[0606] Dalbecco PBS (-) (Nissui Pharmaceutical Co., Ltd.)

[0607] Gelatin (Class A, MP Biomedicals)

[0608] Hoechst (nuclear staining reagent, Hoechst 33342 solution, Dojin Chemical Laboratories Co., Ltd.)

[0609] MitoTracker (MitoTracker Mitochondrion-Selective Probes, Invitrogen company)

[0610] Rhodamine (VectaCell Rhodamine 123, Funakoshi Co., Ltd.)

[0611] 4% paraformaldehyde / phosphate buffer (Nacalai Tesque Co., Ltd.)

[0612] Primary antibody (Anti-Myosin Heavy Chain Purified clone: ​​MF20, eBioscience)

[0613] Secondary antibody (goat anti-mouse IgG Alexa Fluor 555 F(ab)2 fragment (H+L), Life Technologies Japan Ltd.)

[0614] [Cell pre-culture]

[0615] The cells used in the following test examples were pre-cultured.

[0616] Use proliferation medium and grow in T-75 flasks (75cm 2 C2C12 cells were revived in a U-shaped canted neck cell culture flask (Corning Incorporated). The T-75 flask was placed in a CO2 incubator (5% CO2, 37°C, humidified) and the C2C12 cells were cultured. The culture medium was replaced every other day, and the cells were recovered at the time point of reaching 80% confluence and used for the experiment. It should be noted that in the following experiments, the well plates used for culturing C2C12 cells were coated with gelatin using the coating method shown below.

[0617] (1) Sterilize 0.75% gelatin aqueous solution using an autoclave.

[0618] (2) 100 μL of a 0.75% gelatin aqueous solution was added to each well of the plate, and the wells were left to stand in a CO 2 incubator (5% CO 2 , 37° C.) for 2 hours.

[0619] (3) The 0.75% gelatin aqueous solution was removed and the resulting well plate was used.

[0620] [Test Example i1-1: Mitochondrial Activation Test (Evaluation of Activity per Cell)]

[0621] Use proliferation medium at 4 × 10 4 Cells / 0.1mL / well The pre-cultured cells were inoculated into a 96-well plate for fluorescence observation (Optical bottom plate, Nunc). The plate was cultured in a CO2 incubator (5% CO2, 37°C) for 2 days. Then, the culture medium was replaced with a differentiation medium and cultured for 4 days to form myotubes. After the formation of myotubes, the cells were replaced with a differentiation medium containing extract A (Examples i1-1 to i1-3), a differentiation medium containing extract W and 1% (v / v) ethanol (Examples i1-4 to i1-6), a differentiation medium not containing an extract (Comparative Example i1-1), a differentiation medium not containing an extract but containing 1% (v / v) ethanol (Comparative Example i1-2), or a differentiation medium containing 50 μM resveratrol and 1% (v / v) ethanol (positive control i1-1), and cultured separately. 48 hours after the start of culture, the culture was terminated. These were used as test samples for Examples i1-1 to i1-6, Comparative Examples i1-1 to i1-2, or positive control i1-1. In Examples i1-1 to i1-6, the final concentrations of the decomposed extract of bagasse in the differentiation medium are shown in Table 23.

[0622] After removing the culture supernatant, a differentiation medium containing 5 μg / mL Hoechst (nuclear staining reagent) or 10 μg / mL rhodamine (mitochondrial activity staining reagent) was added to the well plate and cultured for 30 minutes at 37°C. Then, the fluorescence intensity was measured separately using a fluorescence well plate reader. The mitochondrial activity of each cell was calculated by dividing the fluorescence intensity of the differentiation medium containing rhodamine by the fluorescence intensity of the differentiation medium containing Hoechst. The relative value (%) in the test samples of Examples i1-1 to i1-3 when the mitochondrial activity in the test sample of Comparative Example i1-1 was set to 100% was obtained. In addition, the relative value (%) in the test samples of Examples i1-4 to i1-6 and the positive control i1 when the mitochondrial activity in the test sample of Comparative Example i1-2 was set to 100% was obtained. The test was performed 5 times each, and the average value is shown in Table 23.

[0623] As shown in Table 23, the mitochondrial activity per cell increased in the test samples of Examples il-l to il-6 to which the extract was added, as compared with the test sample of Comparative Example il-l or il-2 to which the decomposed extract of sugarcane bagasse was not added. The mitochondrial activity also increased in the positive control il-l, and thus it can be said that the test was performed without problems.

[0624] [Table 23]

[0625]

[0626] For the test samples of Example il-5 and Example il-6, the mitochondrial activity was also evaluated for the test samples after 72 hours of culture, using the same method as described above. When the mitochondrial activity in the test sample of Comparative Example il-2 after 72 hours of culture was set to 100% (100.0 ± 1.6%), the mitochondrial activity in the test sample of Example il-5 was 101.7 ± 1.3%, and the mitochondrial activity in the test sample of Example il-6 was 115.0 ± 2.4%. Thus, the mitochondrial activity per cell also increased in the test samples of Example il-5 and Example il-6 to which the extract was added, as compared with the test sample of Comparative Example il-2 to which the decomposed extract of sugarcane bagasse was not added, after 72 hours of culture.

[0627] [Experimental Example il-2: Mitochondrial activation test (evaluation of mitochondrial amount per cell)]

[0628] The myoblast cells were cultured using the same method as in Experimental Example il-l. They were used as the test samples of Examples il-7 to il-11, Comparative Examples il-3 to il-4, or the positive control il-2. Note that in Examples il-7 to il-11, the final concentration in the differentiation medium of the decomposed extract of sugarcane bagasse is shown in Table 24. Then, after removing the culture supernatant, a differentiation medium containing 5 pg / mL of Hoechst (a reagent for staining the nucleus) and 500 nM of MitoTracker (a reagent for staining mitochondria) was added to the well plate, and the fluorescence intensity was measured using the same method as in Experimental Example il-l. The mitochondrial amount per cell was calculated by dividing the fluorescence intensity of the differentiation medium containing MitoTracker by the fluorescence intensity of the differentiation medium containing Hoechst. The relative value (%) was calculated for the test samples of Examples il-7 to il-8, when the mitochondrial amount in the test sample of Comparative Example il-3 was set to 100%. In addition, the relative value (%) was calculated for the test samples of Examples il-9 to il-11 and the positive control il-2, when the mitochondrial activity in the test sample of Comparative Example il-4 was set to 100%. The test was performed five times, and the average values are shown in Table 24.

[0629] As shown in Table 24, the amount of mitochondria per cell increased in the test samples of Examples il-7 to il-11 to which the extract was added, as compared with the test samples of Comparative Examples il-3 or il-4 to which the decomposed extract of sugarcane bagasse was not added. The amount of mitochondria also increased in the positive control il-2, and thus it can be said that the test was performed without problems.

[0630] [Table 24]

[0631]

[0632] The amount of mitochondria was also evaluated for the test samples of Example il-8 and Example il-11 after 72 hours of culture, using the same method as described above. When the amount of mitochondria in the test sample of Comparative Example il-3 after 72 hours of culture was set to 100% (100.0 ± 3.4%), the amount of mitochondria in the test sample of Example il-8 was 104.9 ± 4.5%. In addition, when the amount of mitochondria in the test sample of Comparative Example il-4 was set to 100% (100.0 ± 0.8%), the amount of mitochondria in the test sample of Example il-11 was 107.9 ± 1.9%. Thus, the amount of mitochondria per cell also increased in the test samples of Examples il-8 and il-11 to which the extract was added, as compared with the test samples of Comparative Example il-3 or Comparative Example il-4 to which the decomposed extract of sugarcane bagasse was not added, after 72 hours of culture.

[0633] [Experimental Example il: Myotube cell differentiation promotion test]

[0634] Pre-cultured cells were seeded in a 96-well plate for fluorescence observation at 4 x 10 4 The pre-cultured cells were seeded in a 96-well plate for fluorescence observation at 4 x 10

[0635] At the end of the culture, 4% - paraformaldehyde-phosphate buffer solution was added at 100 μL / well, and left to stand for 15 minutes at 4°C. After the standing, washing was performed 3 times with Dulbecco's PBS (DPBS), and then blocking treatment was performed for 1 hour at room temperature with 0.1% trinitrobenzene-X and 3% bovine serum albumin (BSA) in DPBS. Next, a 3% BSA / DBPS mixed solution containing a first antibody (anti-myosin heavy chain antibody: 300-fold dilution) was added, and left to react overnight at 4°C. After the reaction, washing was performed 3 times with a 3% BSA / DBPS mixed solution. Next, a 3% BSA / DBPS mixed solution containing a second antibody (500-fold dilution) and Hoechst (nuclear staining reagent, 1000-fold dilution) was added, and left to react for 2 hours at room temperature under light shielding, and after the reaction, washing was performed with DPBS. These were used as test samples of Examples i2-1 to i2-2, Comparative Example i2-1 to i2-2, and positive control i2.

[0636] The data of 1 well was used as n = 1, and the total of 5 wells (n = 5) was analyzed. The total number of Hoechst-positive nuclei and the number of MHC-positive nuclei were counted, and the fusion index (the % of MHC+ nuclei) was calculated using the following equation. The average of the fusion index (n = 5) is shown in Table 25.

[0637] Fusion index (the % of MHC+ nuclei) = MHC-positive nuclei number / total nuclei number x 100

[0638] As shown in Table 25, the fusion index increased in the test samples of Examples i2-1 to i2-2 to which the decomposed extract of bagasse was added, as compared with the test sample of Comparative Example i2-1 to which the decomposed extract of bagasse was not added. A significant difference test was performed with respect to Comparative Example i2-1 (two-sided test based on Student's T test), and as a result, the fusion index of the test sample of Example i2-2 was significantly increased as compared with the test sample of Comparative Example i2-1 (p < 0.01). Note that the fusion index increased in the sample of Positive Control i2 as compared with Comparative Example i2-2, and thus it can be said that the test was performed without problems.

[0639] [Table 25]

[0640]

[0641] *) significantly increased (p < 0.01)

[0642] [Experiment j: Test as a bone metabolism improver]

[0643] [Experiment j1: Test for promoting differentiation of osteoblasts]

[0644] [Materials]

[0645] In Test Example Jl, the following materials shown below were used.

[0646] (Cell)

[0647] Mouse calvarial-derived cells MC3T3-E1 (RIKEN CELL BANK, RCB1126)

[0648] (Culture medium)

[0649] Addition of α-MEM medium, 10% FBS, antibiotics

[0650] (Test reagent)

[0651] α-MEM medium (without phenol red, product No. 41061-029, Invitrogen Corporation)

[0652] Penicillin-streptomycin mixed solution (product No. 26253-84, Nacalai Tesque Corporation)

[0653] 0.25% trypsin-EDTA mixed solution (product No. 32777-44, Nacalai Tesque Corporation)

[0654] Dulbecco's PBS (-) (product No. 05913, Nissui Pharmaceutical Co., Ltd.)

[0655] Alkaline phosphatase activity assay kit (LabAssay ALP, product No. 291-58601, Wako Pure Chemical Industries, Ltd.)

[0656] Protein quality assay kit (Micro BCA Protein Assay Reagent Kit, product No. 23235, PIERCE Corporation)

[0657] Cell lysis and protein extraction reagent (Cell-LyE Xl, product No. 300-34761, Wako Pure Chemical Industries, Ltd.)

[0658] 10% neutral buffered formalin solution (product No. 062-01661, Wako Pure Chemical Industries, Ltd.) Calcein AM (product No. PK-CA707-80011, PromoKine Corporation)

[0659] Recombinant bone morphogenetic protein (Bone Morphogenetic Protein-2 (BMP-2), R&D Systems Corporation)

[0660] [Cell pre-culture]

[0661] MC3T3-E1 cells were recovered using proliferation medium in T-75 flasks (75 cm 2 U-shaped cervical cell culture flasks, Corning Incorporated). The T-75 flasks were placed in a CO2 incubator (5% CO2, 37°C, humidified), and C2C12 cells were cultured therein. Medium was replaced once every other day, and the cells were recovered at the time point at which 80% confluency was reached, and used in the experiment.

[0662] [Promotion of osteoblast differentiation test]

[0663] Promotion of osteoblast differentiation in MC3T3-E1 cells was confirmed using alkaline phosphatase (ALP) activity, which is one of the differentiation markers of osteoblasts, as an index.

[0664] The medium was adjusted so that the pre-cultured MC3T3-E1 cells became 1.2 x 10 5 Cells were seeded in a 48-well plate at 1.2 x 10 cells / 0.2 mL / well. The next day, the medium was replaced with a medium containing 100 μg / mL of extract A (Example j1-1), a medium containing 100 μg / mL of extract W and 1% (v / v) ethanol (Example j1-2), a medium containing no extract (Comparative Example j1-1), a medium containing no extract but containing 1% (v / v) ethanol (Comparative Example j1-2), or a medium containing BMP-2 (positive control j1), and cultured for 7 days, 14 days, and 21 days, respectively. After each number of days of culture, the cells were washed once with PBS, and each well plate was stored frozen. The medium was replaced every 3 to 4 days.

[0665] After the cells stored frozen were washed with PBS, lysis was performed with 100 μL / well of a cell lysis agent (Cell-LyE X1 containing 2 mM phenylmethylsulfonyl fluoride (PMSF) ). After the well plate was stirred at room temperature for 30 minutes, centrifugation was performed, and the solution obtained by 5-fold dilution of the supernatant was used as a sample for measurement. Measurement was performed using an alkaline phosphatase activity measurement kit (LabAssay ALP) for the amount of ALP in cells. In this kit, ALP activity was measured from the amount of p-nitrophenol generated per unit protein mass in a certain time. The amount of protein in the solution was measured using a Micro BCA Protein Assay Reagent Kit. The experiment was performed 5 times, and the average value (n = 5) of ALP activity was calculated. The results are shown in Table 26.

[0666] As shown in Table 26, ALP activity was increased in the samples of the examples j1-1 and j1-2 containing the decomposed extract of sugarcane bagasse, as compared with the comparative examples j1-1 and j1-2 not containing the decomposed extract of sugarcane bagasse. The higher the ALP activity, the more it can be said that the differentiation of osteoblasts is promoted. In addition, a significant difference test was performed with the comparative example j1-2 (two-sided test based on Student's T test), and as a result, the samples of the examples j1-1 and j1-2 were significantly increased in ALP activity at 14 days or 21 days of culture, as compared with the test sample of the comparative example j1-2. In the positive control j1, ALP activity was also increased, and thus it can be said that the test was performed without problems.

[0667] [Table 26]

[0668]

[0669] *) Significantly increased at p < 0.01, as compared with the comparative example j1-2

[0670] **) Significantly increased at p < 0.001, as compared with the comparative example j1-2

[0671] [Experiment Example j2: Osteoclast Differentiation Inhibition Test 1]

[0672] [Materials]

[0673] In the experiment example j2, the following materials shown below were used.

[0674] (Cell)

[0675] Human osteoclast precursor cells (Cosmo Bio Co., Ltd. PT-267 Lot. RBW-F-OSH-HBV)

[0676] (Culture medium)

[0677] Culture medium for human osteoclast cells, OSCMHB, Cosmo Bio Co., Ltd.

[0678] (Test reagent)

[0679] Melatonin (M5250, Sigma-Aldrich Corporation)

[0680] TRAP staining kit (AK04F, PMC Corporation)

[0681] [Osteoclast Differentiation Inhibition Test]

[0682] Using the culture medium described above, a 250 pg / mL solution of the extract A was prepared, and used as a test solution (example j2-1).

[0683] Human osteoclast precursor cells were seeded at about 0.3 x 10 5 The cells were seeded at 50 μl / well in 96-well culture plates. Test solutions were added at 50 μl / well, and the cells were incubated for 7 days at 37°C under 5% CO2. The cells were subjected to TRAP staining using a TRAP staining kit, and observed under a microscope. The same test was also performed for a culture medium to which no test solution was added (Comparative Example j2-1), and a culture medium containing 1000 μM of melatonin as a positive control (Positive Control j2). The results of the observation under the microscope are shown in Figure 11 . Figure 11 (a) of Example j2-1, Figure 11 (b) of Comparative Example j2-1, Figure 11 (c) of Positive Control j2.

[0684] As shown in Figure 11 Example j2-1, a decrease in multinucleated mature osteoclasts was observed. On the other hand, in Comparative Example j2-1, which did not contain the decomposition extract of sugar cane residue, no decrease in osteoclasts was observed. A decrease in osteoclasts was also observed in Positive Control j2, and thus it can be said that the test was performed without problems.

[0685] [Experiment Example j3: Osteoclast Differentiation Inhibition Test 2]

[0686] It is known that osteoclasts become multinucleated by fusing with each other when they mature. Therefore, the proportion of mononuclear cells among osteoclasts was measured, and the osteoclast differentiation inhibition effect was confirmed.

[0687] Under the same culture conditions as in Example j2-1, human osteoclast precursor cells were cultured using a culture medium containing the extract A at the concentrations shown in Table 27 (Example j3-1), a culture medium not containing the extract (Comparative Example j3-1), or a culture medium containing melatonin at the concentrations shown in Table 27 as a positive control (Positive Controls j3-1 to j3-2). The proportion of mononuclear cells (%) was calculated by dividing the number of mononuclear cells in the field of view by the total number of cells in the field of view under a microscope. The results are shown in Table 27.

[0688] As shown in Table 27, the proportion of mononuclear cells was increased in Example j3-1 containing the decomposition extract of sugar cane residue, as compared with Comparative Example j3-1 not containing the decomposition extract of sugar cane residue. It can be said that the higher the proportion of mononuclear cells, the more the differentiation of osteoclasts is inhibited. The proportion of mononuclear cells was also increased in Positive Controls j3-1 to j3-2, and thus it can be said that the test was performed without problems.

[0689] [Table 27]

[0690]

Claims

1. An anti-dementia agent comprising a decomposed extract of bagasse as an active ingredient.

2. The anti-dementia agent according to claim 1, wherein The decomposed extract of bagasse is a decomposition treatment liquid obtained by at least one decomposition treatment selected from the group consisting of alkali treatment, hydrothermal treatment, acid treatment, subcritical water treatment, and explosion treatment.

3. The anti-dementia agent according to claim 2, wherein The decomposed extract of bagasse is a fraction obtained by passing the decomposed liquid through a column filled with a fixed carrier.

4. The anti-dementia agent according to claim 3, wherein The fixed carrier is a synthetic adsorbent or an ion exchange resin.

5. The anti-dementia agent according to claim 3, wherein The fixed carrier is a synthetic adsorbent, and the decomposed extract of bagasse is a fraction obtained by eluting components adsorbed on the synthetic adsorbent with at least one solvent selected from the group consisting of water, methanol, ethanol, and a mixture thereof.

6. The anti-dementia agent according to claim 4 or 5, wherein The synthetic adsorbent is an aromatic resin, an acrylic methacrylic resin or an acrylonitrile aliphatic resin.

7. The anti-dementia agent according to claim 2, wherein The decomposed extract of bagasse is a fraction obtained by passing the decomposed liquid through a column filled with a synthetic adsorbent as a fixed carrier and eluting the components adsorbed on the synthetic adsorbent with a mixed solvent of ethanol and water. The synthetic adsorbent is an aromatic resin without substituents. The temperature of the column is 20-60°C, The volume ratio of ethanol to water (ethanol / water) in the mixed solvent is 50 / 50 to 60 / 40.

8. A short-term memory impairment improving / suppressing agent comprising a decomposed extract of sugarcane bagasse as an active ingredient.

9. A flavor improving agent comprising a decomposed extract of bagasse.

10. The flavor improving agent according to claim 9, wherein The decomposed extract of bagasse is a decomposition treatment liquid obtained by at least one decomposition treatment selected from the group consisting of alkali treatment, hydrothermal treatment, acid treatment, subcritical water treatment, and explosion treatment. The flavor improving agent according to claim 10, wherein The decomposed extract of bagasse is a fraction obtained by passing the decomposed liquid through a column filled with a fixed carrier.

12. The flavor improving agent according to claim 11, wherein The fixed carrier is a synthetic adsorbent or an ion exchange resin.

13. The flavor improving agent according to claim 11, wherein The fixed carrier is a synthetic adsorbent, and the decomposed extract of bagasse is a fraction obtained by eluting components adsorbed on the synthetic adsorbent with at least one solvent selected from the group consisting of water, methanol, ethanol, and a mixture thereof.

14. The flavor improving agent according to claim 12 or 13, wherein The synthetic adsorbent is an aromatic resin, an acrylic methacrylic resin or an acrylonitrile aliphatic resin. The flavor improving agent according to claim 10 , wherein The decomposed extract of bagasse is a fraction obtained by passing the decomposed liquid through a column filled with a synthetic adsorbent as a fixed carrier and eluting the components adsorbed on the synthetic adsorbent with a mixed solvent of ethanol and water. The synthetic adsorbent is an aromatic resin without substituents. The temperature of the column is 20-60°C, The volume ratio of ethanol to water (ethanol / water) in the mixed solvent is 50 / 50 to 60 / 40. The flavor improving agent according to any one of claims 9 to 15, which enhances the pleasant flavor of food and drink. The flavor improving agent according to any one of claims 9 to 16, which reduces the unpleasant taste of food and drink. 18 . A food or beverage comprising the flavor improving agent according to claim 9 .

19. A satisfactory flavor enhancer for food and beverages, comprising a decomposed extract of bagasse.

20. An agent for reducing unpleasant taste of food or beverage, comprising a decomposed extract of bagasse.

21. An anti-aging agent comprising a decomposed extract of bagasse as an active ingredient.

22. The anti-aging agent according to claim 21, wherein The decomposed extract of bagasse is a decomposition treatment liquid obtained by at least one decomposition treatment selected from the group consisting of alkali treatment, hydrothermal treatment, acid treatment, subcritical water treatment, and explosion treatment.

23. The anti-aging agent according to claim 22, wherein The decomposed extract of bagasse is a fraction obtained by passing the decomposed liquid through a column filled with a fixed carrier.

24. The anti-aging agent according to claim 23, wherein The fixed carrier is a synthetic adsorbent or an ion exchange resin.

25. The anti-aging agent according to claim 23, wherein The fixed carrier is a synthetic adsorbent, and the decomposed extract of bagasse is a fraction obtained by eluting components adsorbed on the synthetic adsorbent with at least one solvent selected from the group consisting of water, methanol, ethanol, and a mixture thereof.

26. The anti-aging agent according to claim 24 or 25, wherein The synthetic adsorbent is an aromatic resin, an acrylic methacrylic resin or an acrylonitrile aliphatic resin.

27. The anti-aging agent according to claim 22, wherein The decomposed extract of bagasse is a fraction obtained by passing the decomposed liquid through a column filled with a synthetic adsorbent as a fixed carrier and eluting the components adsorbed on the synthetic adsorbent with a mixed solvent of ethanol and water. The synthetic adsorbent is an aromatic resin without substituents. The temperature of the column is 20-60°C, The volume ratio of ethanol to water (ethanol / water) in the mixed solvent is 50 / 50 to 60 / 40.

28. An extracellular matrix degrading enzyme inhibitor comprising a decomposed extract of sugarcane bagasse as an active ingredient.

29. A fibroblast activator comprising a decomposed extract of bagasse as an active ingredient.

Images